The shareholders of Safran (the Company) are invited to an Ordinary and Extraordinary Shareholders' Meeting on Thursday, June 15, 2017 at 2:00 p.m. at Espace Grande Arche – 1, parvis de la Défense – 92044 Paris-La Défense.

- Participating in the Meeting ................................................................. 2
- Agenda ................................................................................................. 8
- Report on the proposed resolutions and text of the proposed resolutions ......................................................... 10
- Profiles of the nominees to the Board of Directors .......................................................................................... 42
- Summary table of authorizations for the Board of Directors submitted for approval at the Annual General Meeting ................................................................. 46
- Summary table of authorizations in force already granted to the Board of Directors ........................................... 48
PARTICIPATING IN
THE MEETING

How to participate in the Meeting

All shareholders are entitled to participate in the Meeting, whether in person, by proxy or by casting a postal or online vote, regardless of the number of shares owned, in accordance with French law.

In accordance with Article R.225-86 of the French Commercial Code (Code de commerce), in order for shareholders to attend the Annual General Meeting, cast a postal or online vote or appoint a proxy, their shares must be recorded in their name or in the name of an authorized intermediary on their behalf no later than at zero hours (CET) on the second business day preceding the Meeting (i.e., June 13, 2017) as follows:

+ for REGISTERED shares: in the Company’s share register managed by BNP Paribas Securities Services;
+ for BEARER shares: in a securities account managed by an authorized intermediary, as provided for in Article L.211-3 of the French Monetary and Financial Code (Code monétaire et financier).

The recording of shares in bearer share accounts managed by an authorized intermediary must be certified by a share ownership certificate issued by the latter. In the absence of the certificate, drawn up in your name or in the name of the registered intermediary acting on your behalf, should be attached to the proxy/postal voting form or to the admittance card request.

All Safran shareholders may request an admittance card, cast their vote or appoint a proxy online prior to the Meeting via the Votaccess secure voting platform as from May 26, 2017. The deadline for requesting an admittance card, voting and appointing/revoking a proxy online is 3:00 p.m. (CET), June 14, 2017. Shareholders are advised not to wait until the day before the Meeting to request their admittance card or register their voting instructions.

How to exercise your voting rights

Shareholders may exercise their voting rights in any of the following ways:

**Case 1:** they may attend the Meeting in person;

**Case 2:** they may give proxy to the Chairman of the Meeting or send a proxy form to the Company without specifying their representative, in which case the Chairman of the Meeting will vote to adopt the proposed resolutions presented or approved by the Board of Directors and vote against all other proposed resolutions;

**Case 3:** they may give proxy to another shareholder, their spouse, their partner with whom they have entered into a civil union or any other individual or legal entity of their choice in accordance with the requirements of Article L.225-106 of the French Commercial Code;

**Case 4:** they may cast a postal vote; or

**Case 5:** they may give online voting instructions.

Once you have cast a postal or online vote, appointed a proxy or requested an admittance card, you will not be able to participate in the Meeting in another way.

April 24, 2017
Case 1:
you plan to attend the Meeting in person

Holders of registered and administered registered shares

Holders of registered or administered registered shares planning to attend the Meeting in person should complete the proxy/postal voting form attached to the Notice of Meeting (checking the box corresponding to their choice) and send it in the enclosed prepaid envelope or by letter addressed to BNP Paribas Securities Services, CTS Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93761 Pantin Cedex, France.

You will receive your admittance card by return mail. If you do not receive your admittance card in time you will still be able to attend the Meeting subject to providing proof of identity.

In the event that you have not received your admittance card the day before the Meeting, you can also call one of the following numbers: 0826 100 374 (France only) or 00 33 1 57 43 75 00 (outside France) to obtain your admittance card number, which will facilitate entry to the Meeting.

Holders of bearer shares

Holders of bearer shares planning to attend the Meeting in person should request a share ownership certificate from their authorized intermediary. The latter will forward the certificate to BNP Paribas Securities Services, CTS Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93761 Pantin Cedex, France, which will then send an admittance card by post.

If you do not receive your admittance card by zero hours (CET) on the second business day preceding the Meeting (i.e., June 13, 2017) you should ask your authorized intermediary to issue you with a certificate proving that you own the shares and are therefore entitled to attend the Meeting.

Shareholders may request an admittance card online

The admittance card will be sent either by email or by post, at your discretion.

Shareholders can also download and print their admittance card online.

RESULTS OF REGISTERED AND ADMINISTERED REGISTERED SHARES

Holders of registered and administered registered shares may request an admittance card online, via the Votaccess secure platform. This platform can be accessed from the Planetshares website at https://planetshares.bnpparibas.com.

Holders of registered shares should log on to the Planetshares website with the username and password they use to access their share account.

Holders of administered registered shares should log on to the Planetshares website with the username that appears in the top right-hand corner of the voting form that was posted along with the Notice of Meeting.

In the event that you misplace or forget your username and/or password, call one of the following numbers: 0826 100 374 (France only) or 00 33 1 57 43 75 00 (outside France).

After logging on, registered and administered registered shareholders should follow the on-screen instructions to access Votaccess, where they can request an admittance card online.

HOLDERS OF BEARER SHARES

Holders of bearer shares should find out whether their custodian is connected to the Votaccess platform and if so, whether this access is subject to specific terms and conditions.

Only holders of bearer shares whose custodian is connected to Votaccess can request an admittance card online.

If your custodian is connected to Votaccess, you should log on to your custodian’s website with your usual username and password. You should then click on the icon that appears on the line corresponding to your Safraan shares and follow the on-screen instructions to access the Votaccess platform and request an admittance card.
Case 2: 
you wish to give proxy to the Chairman of the Meeting or send a proxy form to the Company without specifying a representative

The Chairman of the Meeting will vote to adopt the proposed resolutions presented or approved by the Board of Directors and vote against all other proposed resolutions.

Holders of registered and administered registered shares

POSTAL PROXY
Holders of registered or administered registered shares wishing to give proxy to the Chairman of the Meeting should complete and sign the proxy/postal voting form attached to the Notice of Meeting (checking the box corresponding to their choice) and send it in the enclosed prepaid envelope or by letter addressed to BNP Paribas Securities Services, CTS Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93761 Pantin Cedex, France.

ONLINE PROXY
Holders of registered or administered registered shares can give proxy to the Chairman of the Meeting online via Votaccess by logging on to the Planetshares website at https://planetshares.bnpparibas.com.

Holders of registered shares should log on to the Planetshares website with the username and password they use to access their share account.

Holders of administered registered shares should log on to the Planetshares website with the username that appears in the top right hand corner of the voting form that was posted along with the Notice of Meeting.

In the event that you misplace or forget your username and/or password, call one of the following numbers: 0826 100 374 (France only) or 00 33 1 37 43 75 00 (outside France).

Holders of bearer shares

POSTAL PROXY
Holders of bearer shares wishing to give proxy to the Chairman of the Meeting may request a unique proxy form from their authorized intermediary. This request must be received by the authorized intermediary no later than six days before the date of the Meeting (i.e., June 9, 2017). The authorized intermediary will then send the duly completed and signed voting form along with a share ownership certificate to BNP Paribas Securities Services.

ONLINE PROXY
Holders of bearer shares whose custodian is connected to Votaccess should log on to their custodian’s website with their usual username and password. They should then click on the icon that appears on the line corresponding to their Safran shares and follow the on-screen instructions.

Case 3: 
you wish to give proxy to another person or entity

You may give proxy to another shareholder, your spouse, your partner with whom you have entered into a civil union or any other individual or legal entity of your choice in accordance with the provisions of Article L.225-106 of the French Commercial Code.

Appointing a proxy

You may appoint a proxy by post or online.

Holders of registered and administered registered shares

POSTAL PROXY
Holders of registered or administered registered shares wishing to give proxy to another person or entity should complete and sign the proxy/postal voting form attached to the Notice of Meeting (checking the box corresponding to their choice) and send it in the enclosed prepaid envelope or by letter addressed to BNP Paribas Securities Services, CTS Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93761 Pantin Cedex, France.

April 24, 2017
ONLINE PROXY

Holders of registered or administered registered shares can give proxy online via Votaccess by logging on to the Planetshares website at https://planetshares.bnpparibas.com.

Holders of registered shares should log on to the Planetshares website with the username and password they use to access their share account.

Holders of administered registered shares should log on to the Planetshares website with the username that appears in the top right-hand corner of the voting form that was posted along with the Notice of Meeting.

In the event that you misplace or forget your username and/or password, call one of the following numbers: 0826 100 374 (France only) or 00 33 1 57 43 75 00 (outside France).

Holders of bearer shares

POSTAL PROXY

Holders of bearer shares wishing to give proxy to another person or entity may request a unique proxy form from their authorized intermediary. This request must be received by the authorized intermediary no later than six days before the date of the Meeting (i.e., June 5, 2017). The authorized intermediary will then send the duly completed and signed voting form along with a share ownership certificate to BNP Paribas Securities Services.

PROXY GIVEN ONLINE OR VIA EMAIL IN ACCORDANCE WITH ARTICLE R.225-79 OF THE FRENCH COMMERCIAL CODE

Online

Holders of bearer shares whose custodian is connected to Votaccess should log on to their custodian’s website with their usual username and password. They should then click on the icon that appears on the line corresponding to their Safran shares and follow the on-screen instructions.

Email

Holders of bearer shares whose custodian is not connected to Votaccess can send an email to paris.bpq2s.france.cts.mandats@bnpparibas.com with the following information: the name of the company concerned (Safran), the date of the Meeting (June 15, 2017), their name, address and banking details, as well as the name and, if possible, the address of their proxy.

Holders of bearer shares must ask the authorized intermediary managing their securities account to send a share ownership certificate to the AGM Department (Service Assemblées Générales) of BNP Paribas Securities Services by post or email.

Only notifications of proxies can be sent to the above email address; all other unrelated requests or notifications will not be considered and/or dealt with.

Digital copies of the proxy form must be signed in order to be valid. The forms must be received by 3:00 p.m. (CET) the day before the Meeting (i.e., June 14, 2017).

Revoking a proxy

You can revoke your proxy by following the same procedure as when you appointed the proxy.

BY POST

To appoint a new proxy after revoking your previous proxy, you must request a “Change of proxy” form from BNP Paribas Securities Services (for holders of registered shares) or from your authorized intermediary (for holders of bearer shares). The completed form must be returned to BNP Paribas Securities Services, CTS Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93761 Pantin Cedex, France, at the latest three calendar days before the Meeting, (i.e., by zero hours [CET] on June 12, 2017). Holders of bearer shares must ask the authorized intermediary managing their securities account to send a share ownership certificate to the AGM Department (Service Assemblées Générales) of BNP Paribas Securities Services.

ONLINE

You can also revoke your proxy online by following the same procedure as when you appointed the proxy.

Holders of registered and administered registered shares

Holders of registered and administered registered shares can revoke their proxy and, where applicable, appoint a new proxy by logging on to Votaccess via the Planetshares website at https://planetshares.bnpparibas.com.

Holders of bearer shares

Holders of bearer shares whose custodian is connected to Votaccess can revoke their proxy and, where applicable, appoint a new proxy by logging on to their custodian’s website with their usual username and password.

Holders of bearer shares whose custodian is not connected to Votaccess can revoke or change their proxy electronically in accordance with the provisions of Article R.225-79 of the French Commercial Code.

In this case, shareholders should send an email to paris.bpq2s.france.cts.mandats@bnpparibas.com with the following information: the name of the company concerned (Safran), the date of the Meeting (June 15, 2017), their name, address and banking details, as well as the name and, if possible, the address of their proxy.

To appoint a new proxy after revoking a previous proxy, holders of bearer shares must obtain a “Change of proxy” form from their custodian. The completed form...
must be returned by email to paris.bp2s.france.cts.mandats@bnpparibas.com. Holders of bearer shares must ask the authorized intermediary managing their securities account to send a share ownership certificate to the AGM Department (Service Assemblées Générales) of BNP Paribas Securities Services by post or email.

Only notifications of revoked proxies or of a change of proxy can be sent to the above email address; all other unrelated requests or notifications will not be considered and/or dealt with.

Digital copies of the “Change of proxy” form must be signed in order to be valid. Emails and forms notifyin revoked proxies or a change of proxy must be received by 5.00 p.m. (CET) the day before the Meeting (i.e., June 14, 2017).

Case 4:
you wish to cast a postal vote

Holders of registered and administered registered shares

Holders of registered or administered registered shares wishing to cast a postal vote should complete and sign the proxy/postal voting form attached to the Notice of Meeting (checking the box corresponding to their choice) and send it in the enclosed prepaid envelope or by letter addressed to BNP Paribas Securities Services, CTS Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93701 Pantin Cedex, France.

Holders of bearer shares

Holders of bearer shares wishing to cast a postal vote may request a unique postal voting form from their authorized intermediary. This request must be received by the authorized intermediary no later than six days before the date of the Meeting (i.e., June 9, 2017). The authorized intermediary will then send the duly completed and signed voting form along with a share ownership certificate to BNP Paribas Securities Services.

Duly completed and signed postal voting forms must reach BNP Paribas Securities Services at least three days before the Meeting (i.e., by zero hours [CET] on June 12, 2017).

Case 5:
you wish to register your voting instructions online

Holders of registered shares

Holders of registered shares wishing to register their voting instructions online should log on to Votaccess with the username and password they use to access their registered share account on the Planetshares website at https://planetshares.bnpparibas.com.

Holders of administered registered shares

Holders of administered registered shares wishing to register their voting instructions online should log on to the Planetshares website with the username that appears in the top right-hand corner of the voting form that was posted along with the Notice of Meeting.

Procedure for holders of registered and administered registered shares

In the event that you misplace or forget your username and/or password, call one of the following numbers: 0826 100 374 (France only) or 00 33 1 57 43 75 00 (outside France).

After logging on, you should follow the on-screen instructions to access Votaccess, where you can register your voting instructions. From this website, you can also consult official documentation pertaining to the Annual General Meeting.

Procedure for holders of bearer shares

Holders of bearer shares whose custodian is connected to Votaccess should log on to their custodian’s website with their usual username and password. They should then click on the icon that appears on the line corresponding to their Safiran shares and follow the on-screen instructions to access the Votaccess platform. From this website, they can also consult official documentation pertaining to the Annual General Meeting.

April 24, 2017
Sale of shares prior to the Annual General Meeting

Shareholders may transfer ownership of some or all of their shares at any time

(i) If the sale occurs before zero hours (CET) on June 13, 2017, the postal vote, proxy, admittance card and any share ownership certificates will be canceled or modified accordingly. In such an event, the authorized intermediary (as provided for in Article L211-3 of the French Monetary and Financial Code) must notify the Company or BNP Paribas Securities Services of the sale and forward the required information.

(ii) If the sale occurs after zero hours (CET) on June 13, 2017, it will not be notified by the authorized intermediary and will not be taken into consideration by the Company, regardless of the means of communication, notwithstanding any agreement to the contrary.

Written questions
Requests to add items to the agenda or to submit proposed resolutions

Submitting written questions

Shareholders may submit written questions to the Company as from the publication date of the documentation to be submitted to the Shareholders’ Meeting on the Company’s website (see below). Written questions must be addressed to the Chairman of the Board of Directors at the Company’s registered office (2, boulevard du Général Martial Valin, 75724 Paris Cedex 15, France) by recorded delivery with acknowledgement of receipt, or to the following email address: actionnaire.individuel@safiran-group.com, no later than the fourth business day preceding the Meeting (i.e., by zero hours [CET] on June 9, 2017). Written questions must be accompanied by a share ownership certificate. Questions covering the same or similar content may be answered jointly. A written question will be considered answered when such answer is published on the website of the Company in a dedicated Q&A section.

Requesting to add items to the agenda or to submit proposed resolutions

Requests to add items to the agenda or to submit proposed resolutions must be addressed to the Company’s registered office (Shareholder Relations Department, 2, boulevard du Général Martial Valin, 75724 Paris Cedex 15, France) by recorded delivery with acknowledgement of receipt, or to the following email address: actionnaire.individuel@safiran-group.com, within twenty calendar days (i.e., by zero hours [CET] on May 15, 2017) of the publication (April 24, 2017) of the Notice of Meeting in the French legal gazette (Bulletin des Annonces Légales Obligatoires – BALO) and must be received by the Company no later than twenty-five days (i.e., May 21, 2017) before the date of the Annual General Meeting. In order to make such a request, shareholders must provide evidence, at the date the request is made, that they own or represent the portion of capital provided for in Article R.225-71 of the French Commercial Code, either in the Company’s share register managed by BNP Paribas Securities Services or in a bearer shares account managed by an authorized intermediary, as provided for in Article L211-3 of the French Monetary and Financial Code.

Requests to add items to the agenda or to submit proposed resolutions must be accompanied by a share ownership certificate. Shareholders are reminded that for such requests to be taken into account, the shareholders concerned must provide a new share ownership certificate before the Shareholders’ Meeting justifying the registration of their shares in the same accounts, at zero hours (CET) two business days preceding the Shareholders’ Meeting to which the agenda items or proposed resolutions are submitted (i.e., June 13, 2017), under the same conditions as those indicated above. Any additional agenda items or proposed resolutions requested by shareholders will be published on the Company’s website at http://www.safiran-group.com (Finance section).

Documents made available to shareholders

In accordance with the applicable legal and regulatory provisions, all documents that must be made available to shareholders within the context of the Shareholders’ Meeting may be obtained from the Safran Shareholder Relations Department at the registered office located at 2, boulevard du Général Martial Valin, 75015 Paris, France. These documents may also be obtained by shareholders on request from BNP Paribas Securities Services as from the publication of the Notice of Meeting in the BALO, or fifteen days before the Shareholders’ Meeting, depending on the document concerned.

The documentation provided for by Article R.225-73-1 of the French Commercial Code will be available on the Company’s website at http://www.safiran-group.com (Finance section), no later than twenty one days before the Shareholders’ Meeting.

April 24, 2017
AGENDA

ORDINARY RESOLUTIONS

First resolution: Approval of the parent company financial statements for the year ended December 31, 2016
Second resolution: Approval of the consolidated financial statements for the year ended December 31, 2016
Third resolution: Appropriation of profit for the year and approval of the recommended dividend
Fourth resolution: Approval of related-party commitments governed by Article L.225-42-1 of the French Commercial Code, given to Ross McIntyre (Chairman of the Board of Directors) concerning pension benefits
Fifth resolution: Approval of related-party commitments governed by Article L.225-42-1 of the French Commercial Code, given to Philippe Petitcolin (Chief Executive Officer) concerning pension benefits
Sixth resolution: Approval of related-party agreements governed by Article L.225-38 of the French Commercial Code, entered into with the French State
Seventh resolution: Re-appointment of Odile Desforges as a Director
Eighth resolution: Appointment of Hélène Auriol Potier as a Director
Ninth resolution: Appointment of Patrick Péleta as a Director
Tenth resolution: Appointment of Sophie Zurquiyah as a Director
Eleventh resolution: Advisory vote on the components of compensation due or awarded for 2016 to Ross McIntyre, Chairman of the Board of Directors
Twelfth resolution: Advisory vote on the components of compensation due or awarded for 2016 to Philippe Petitcolin, Chief Executive Officer
Thirteenth resolution: Approval of the compensation policy applicable to the Chairman of the Board of Directors
Fourteenth resolution: Approval of the compensation policy applicable to the Chief Executive Officer
Fifteenth resolution: Authorization for the Board of Directors to carry out a share buyback program

EXTRAORDINARY RESOLUTIONS

Sixteenth resolution: Amendment to Article 25 of the Company’s bylaws in order to raise the age limit for serving as Chief Executive Officer or Deputy Chief Executive Officer to 68
Seventeenth resolution: Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders, which may not be used during, or in the run-up to, a public offer for the Company’s shares
Eighteenth resolution: Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, by way of a public offer, which may not be used during, or in the run-up to, a public offer for the Company’s shares
Nineteenth resolution: Authorization for the Board of Directors to issue shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company, which may not be used during, or in the run-up to, a public offer for the Company’s shares
Twentieth resolution: Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, through a private placement governed by Article L.411-2-II of the French Monetary and Financial Code, which may not be used during, or in the run-up to, a public offer for the Company’s shares
Twenty-first resolution: Authorization for the Board of Directors to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights for existing shareholders (pursuant to the 17th, 18th, 19th or 20th resolutions), which may not be used during, or in the run-up to, a public offer for the Company’s shares
Twenty-second resolution: Authorization for the Board of Directors to increase the Company’s capital by capitalizing reserves, retained earnings or additional paid-in capital, which may not be used during, or in the run-up to, a public offer for the Company’s shares
Twenty-third resolution: Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders, which may only be used during, or in the run-up to, a public offer for the Company’s shares

April 24, 2017
Twenty-fourth resolution: Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, by way of a public offer, which may only be used during, or in the run-up to, a public offer for the Company's shares.

Twenty-fifth resolution: Authorization for the Board of Directors to issue shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company, which may only be used during, or in the run-up to, a public offer for the Company's shares.

Twenty-sixth resolution: Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, through a private placement governed by Article L.411.2-8 of the French Monetary and Financial Code, which may only be used during, or in the run-up to, a public offer for the Company's shares.

Twenty-seventh resolution: Authorization for the Board of Directors to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights (pursuant to the 23rd, 24th, 25th or 26th resolutions), which may only be used during, or in the run-up to, a public offer for the Company's shares.

Twenty-eighth resolution: Authorization for the Board of Directors to increase the Company's capital by capitalizing reserves, retained earnings or additional paid-in capital, which may only be used during, or in the run-up to, a public offer for the Company's shares.

Twenty-ninth resolution: Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares to employees who are members of a Safran group employee savings plan, without pre-emptive subscription rights for existing shareholders.

Thirty-first resolution: Authorization for the Board of Directors to reduce the Company's capital by canceling treasury shares.

Thirty-second resolution: Powers to carry out formalities.

RESOLUTION CONCERNING POWERS TO CARRY OUT FORMALITIES
REPORT ON THE PROPOSED RESOLUTIONS AND TEXT OF THE PROPOSED RESOLUTIONS

The proposed resolutions that will be submitted for shareholder approval at Safran’s Annual General Meeting on June 15, 2017 are presented below.

Each of the resolutions is preceded by an explanatory paragraph providing a description of the resolution and setting out the reasons why it is being proposed.

ORDINARY RESOLUTIONS

Approval of the parent company and consolidated financial statements for the year ended December 31, 2016

PRESENTATION OF THE 1st AND 2nd RESOLUTIONS

Shareholders are invited to approve the parent company and consolidated financial statements for the year ended December 31, 2016 as well as the expenses incurred during the year that are not deductible for tax purposes (company vehicles)

- The parent company financial statements show that the Company ended 2016 with profit of €969 million.
- The consolidated financial statements show attributable profit for the year amounting to €1,089 million (€4.00 per share).

TEXT OF THE FIRST RESOLUTION

Approval of the parent company financial statements for the year ended December 31, 2016

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the management report prepared by the Board of Directors and the Statutory Auditors’ report on the parent company financial statements, the shareholders approve the financial statements of the parent company for the year ended December 31, 2016 as presented – showing profit for the year of €969,870,637.75 – together with the transactions reflected in these financial statements and referred to in these reports.

Pursuant to Article 223 quater of the French Tax Code (Code général des impôts), the shareholders approve the non-deductible expenses governed by Article 39-4 of said Code, which totaled €69,249 and gave rise to a tax charge of €23,842.

TEXT OF THE SECOND RESOLUTION

Approval of the consolidated financial statements for the year ended December 31, 2016

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the management report prepared by the Board of Directors and the Statutory Auditors’ report on the consolidated financial statements, the shareholders approve the consolidated financial statements for the year ended December 31, 2016 as presented, together with the transactions reflected in these financial statements and referred to in these reports.

April 24, 2017
Appropriation of profit for the year and approval of the recommended dividend

PRESENTATION OF THE 3RD RESOLUTION

The Company’s distributable profit for 2016 totals €2,427.7 million, breaking down as €969.8 million in profit for the year plus €1,457.8 million in retained earnings brought forward from the previous year.

The Board of Directors is recommending a total dividend payout of €633.8 million, representing a per-share dividend of €1.52, up 10.1% on 2015. In line with the Group’s practice, this dividend payout represents approximately 40% of adjusted profit for the year.

An interim dividend of €0.69 per share was paid on December 21, 2016 with the ex-dividend date having been set as December 19, 2016. If the 3rd resolution is approved, the ex-dividend date for the balance of the 2016 dividend – corresponding to €0.83 per share – will be set as June 19, 2017, and the dividend payment will be made on June 21, 2017.

The remaining €1,793.8 million of distributable profit would be allocated to retained earnings.

Individual shareholders domiciled for tax purposes in France are eligible for 40% tax relief on the full amount of their interim dividend, as provided for under Article 158, 3-2° of the French Tax Code.

They also qualify for this 40% tax relief on the full amount of the balance of the dividend payment.

TEXT OF THE THIRD RESOLUTION

Appropriation of profit for the year and approval of the recommended dividend

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, and based on the Board of Directors’ recommendation, the shareholders resolve to appropriate the profit for the year ended December 31, 2016 as follows:

<table>
<thead>
<tr>
<th>Appropriation:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Profit for 2016</td>
<td>€969,870,637.75</td>
</tr>
<tr>
<td></td>
<td>Retained earnings(^{(1)})</td>
<td>€1,457,860,822.84</td>
</tr>
<tr>
<td></td>
<td>Profit available for distribution</td>
<td>€2,427,731,460.59</td>
</tr>
<tr>
<td></td>
<td>Dividend</td>
<td>€633,864,969.20</td>
</tr>
<tr>
<td></td>
<td>Retained earnings</td>
<td>€1,793,846,491.39</td>
</tr>
</tbody>
</table>

\(^{(1)}\) including €863,202,90 corresponding to the 2015 dividend due on shares held in treasury at the dividend payment date.

Accordingly, the dividend paid will be €1.52 per share.

An interim dividend of €0.69 per share was paid on December 21, 2016. The ex-dividend date for the remaining payout of €0.83 per share will be June 19, 2017 and the dividend will be paid on June 21, 2017.

Individual shareholders domiciled for tax purposes in France are eligible for 40% tax relief on the full amount of their interim dividend and the remainder of the dividend, as provided for under Article 158, 3-2° of the French Tax Code.

The shareholders resolve that dividends not payable on shares held in treasury will be credited to retained earnings.

The shareholders note that dividends paid for the past three years were as follows:

<table>
<thead>
<tr>
<th>Number of shares carrying dividend rights (^{(1)})</th>
<th>Net dividend per share</th>
<th>Total payout (^{(2)})</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015 416,410,610 (^{(2)})</td>
<td>€1.38</td>
<td>€574,637,624.40</td>
</tr>
<tr>
<td>2014 416,459,463 (^{(3)})</td>
<td>€1.20</td>
<td>€499,711,590.56</td>
</tr>
<tr>
<td>2013 416,450,981 (^{(4)})</td>
<td>€1.12</td>
<td>€466,423,898.72</td>
</tr>
</tbody>
</table>

\(^{(1)}\) Total number of shares making up the Company’s capital (417,029,585) less the number of Safran shares held in treasury at the dividend payment date.

\(^{(2)}\) An interim dividend (€0.69) was paid on 416,395,584 shares and the remainder of the dividend (€0.79) was paid on 416,410,610 shares.

\(^{(3)}\) An interim dividend (€0.65) was paid on 416,395,584 shares and the remainder of the dividend (€0.64) was paid on 416,450,981 shares.

\(^{(4)}\) An interim dividend (€0.64) was paid on 416,448,461 shares and the remainder of the dividend (€0.64) was paid on 416,450,981 shares.

\(^{(5)}\) Fully eligible for the 40% tax relief provided for under Article 158, 3-2° of the French Tax Code.
Related-party commitments

PRESENTATION OF THE 4th AND 5th RESOLUTIONS

The 4th and 5th resolutions concern related-party commitments governed by Articles L225-38 and L225-42-1 of the French Commercial Code (Code de commerce) given since the beginning of 2017 and prior to the notice of the June 15, 2017 Annual General Meeting, as described in the Statutory Auditors’ special report (see section 7.6 of the 2016 Registration Document).

Related-party commitments given to executive corporate officers correspond to benefits due or potentially due (i) as a result of the termination or a change in their duties, and (ii) in relation to pension plans and personal risk insurance. In early 2017 the Company gave a number of commitments relating to pension benefits that are subject to this procedure.

At its meeting on April 23, 2015, having appointed Ross McIntyre as Chairman of the Board of Directors and Philippe Petitcolin as Chief Executive Officer, the Board decided – in accordance with Article L. 225-42-1 of the French Commercial Code – to authorize Ross McIntyre and Philippe Petitcolin to continue to be beneficiaries under the defined benefit supplementary pension plan (Article 39) and the defined contribution supplementary pension plan (Article 83) set up in France (subject to the same terms and conditions as the other plan members). These commitments were approved by shareholders at the May 19, 2016 Annual General Meeting.

The Board of Directors considers it necessary to supplement the statutory basic and top-up pension plans of its senior managers as the benchmark surveys carried out in relation to comparable groups in France showed that this component of Safran’s compensation policy is not sufficiently competitive to attract and retain the best talent. This is particularly important because:

- as a result of its demographic profile, in the coming years the Group will need to recruit senior managers in the international market, which is highly competitive; and
- like other groups, Safran will probably have to deal with higher turnover of managerial-grade staff in the future than is currently the case.

Consequently, the Board decided to modify Safran’s supplementary pension plans in order to align them with future needs, bring them more into line with market practices and enhance the Group’s appeal.

The underlying aim of these changes is to increase the replacement rate of the managerial-grade staff concerned (when they take their pension after 20 years’ worth of contributions) as compared with what they would potentially have received under other existing plans (statutory and supplementary). This will be achieved by putting in place new defined contribution plans (without a guaranteed replacement rate).

The new pension system comprises three stages:

- Closing the current defined benefit plan to new entrants and freezing existing beneficiaries' entitlements as at December 31, 2016.
  - To compensate for the closure of the plan, new plans will be set up for senior managers in France as from January 1, 2017 in addition to the defined contribution plan already in place.
  - Putting in place an additional component of the current defined contribution plan.
  - Setting up a new defined contribution plan (Article 83).

Closing the defined benefit plan to new entrants and freezing existing entitlements

Only beneficiaries who have five years of service with the Group at December 31, 2017 will be eligible to receive benefits under this plan (a closed group). Their benefit entitlements will remain subject to the terms and conditions set when the plan was originally put in place.

Conditional entitlements under the plan will be frozen as at December 31, 2016. This means that for members of the closed group:

- the reference compensation used to calculate the conditional entitlements will be calculated based on the average of beneficiaries’ gross fixed and variable compensation for the years 2014 to 2016 (revalued annually using the actuarial assumptions applied to calculate retirement benefit provisions); and
- the length of service taken into account for the plan will have a cut-off date of December 31, 2016 and no additional conditional entitlements will be accrued under the plan for any service after that date.

Mandatory collective defined contribution plan (Additional Defined Contribution Plan)

This plan will apply to all managerial-grade staff whose gross annual compensation for the calendar year preceding the assessment date (Y-1) is equal to or higher than four times the social security ceiling (PASS) for Y-1.

The contributions will be based on Tranches A, B and C of compensation as defined for the calculation of statutory top-up pensions (ARRCO-AGIRC plans).

Entitlements under the plan will accrue in return for the payment of monthly contributions representing 6% of Tranche A, 6% of Tranche B and 6% of Tranche C. All of these monthly payments are borne in full by the Company (in addition to the 2% contribution already paid by the Company under the existing defined contribution supplementary pension plan).

The taxes and social security contributions on the monthly payments are also borne in full by the Company.

Voluntary collective defined contribution plan

Unlike for the Company’s defined benefit plan, this plan does not provide a guaranteed level of retirement benefits.

It is a voluntary plan which eligible beneficiaries can decide whether or not to sign up to.

Eligible beneficiaries correspond to top executives ( hors statut) whose reference compensation (fixed compensation and annual bonus) for the calendar year preceding the assessment date (Y-1) is equal to or higher than seven times the social security ceiling (PASS) for Y-1.

The reference compensation for Y-1 is used to calculate the contributions to the plan. This reference compensation corresponds to the beneficiary’s full-time basic fixed compensation plus the short-term bonus for the year concerned and excludes any other components of compensation.

April 24, 2017
In order for entitlements to accrue, the plan provides for:

- payment by the Company to an insurer of monthly contributions, the rate of which is set based on the beneficiary’s reference compensation for year Y-1 (Insurer Contribution) and may amount to up to 12.7% of that reference compensation;

- payment by the Company to the beneficiary of a cash amount corresponding to the Insurer Contribution (Additional Payment). The plan provides for upfront taxation so that the capital accrued and received on beneficiaries’ retirement is net of tax and social security contributions.

The above payments are borne in full by the Company and subject to social security contributions in the same way as salaries.

Application of the new system to the Chairman of the Board of Directors

At its meeting on March 29, 2017, the Board of Directors decided that the Chairman of the Board could be a beneficiary under the new supplementary pension plan system.

Concerning the voluntary collective defined contribution plan, the Insurer Contribution and the Additional Payment to the Chairman of the Board for 2017 will each correspond to 11.29% of his reference compensation (i.e., a total of 22.58%). These amounts are estimated to represent €57,690 each (i.e., a total of €115,381).

The expenses payable by Safran under the Additional Defined Contribution Plan for 2017 are estimated at €18,829.

These commitments form an indivisible whole which the shareholders are invited to approve in the 4th resolution.

Application of the new system to the Chief Executive Officer

At its meeting on March 29, 2017, the Board of Directors decided that the Chief Executive Officer could be a beneficiary under the new supplementary pension plan system.

Concerning the new voluntary collective defined contribution plan, the Insurer Contribution and the Additional Payment to the Chief Executive Officer for 2017 will each correspond to 12.73% of his reference compensation (i.e., a total of 25.47%). These amounts are estimated to represent €154,747 each (i.e., a total of €309,493).

The expenses payable by Safran under the Additional Defined Contribution Plan for 2017 are estimated at €18,829.

These commitments form an indivisible whole which the shareholders are invited to approve in the 5th resolution.

TEXT OF THE FOURTH RESOLUTION

Approval of related-party commitments governed by Article L.225-42-1 of the French Commercial Code, given to Ross McInnes (Chairman of the Board of Directors) concerning pension benefits

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the Statutory Auditors’ special report on related-party commitments governed by Article L.225-42-1 of the French Commercial Code, the shareholders approve (i) the commitments described therein given to Ross McInnes (Chairman of the Board of Directors) concerning Safran’s new pension plan system and (ii) the related provisions of said report.

TEXT OF THE FIFTH RESOLUTION

Approval of related-party commitments governed by Article L.225-42-1 of the French Commercial Code, given to Philippe Petitcolin (Chief Executive Officer) concerning pension benefits

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the Statutory Auditors’ special report on related-party commitments governed by Article L.225-42-1 of the French Commercial Code, the shareholders approve (i) the commitments described therein given to Philippe Petitcolin (Chief Executive Officer) concerning Safran’s new pension plan system and (ii) the related provisions of said report.

Related-party agreements

PRESENTATION OF THE 6th RESOLUTION

In the 6th resolution, shareholders are asked to approve related-party agreements governed by Article L.225-38 of the French Commercial Code, as described in the Statutory Auditors’ special report (see section 7.6 of the 2016 Registration Document).

Related-party agreements that require shareholder approval include agreements – other than those falling within the scope of routine operations – that are entered into between the Company and (i) any companies with which it has a member of management in common, or (ii) a shareholder owning more than 10% of the Company's voting rights.

Approval of related-party agreements governed by Article L.225-38 of the French Commercial Code entered into with the French State

Directors concerned:
- Lucie Muniesa, representing the French State (shareholder);
- Patrick Gandil, Director put forward by the French State;
- Vincent Imbert, Director put forward by the French State.
Shareholder concerned: the French State (shareholder owning more than 10% of the Company’s voting rights).

April 24, 2017
In order to boost competitive performance and safeguard the future of the European space launch vehicle sector, faced with increasing international competition, Safran and Airbus joined forces in the launch vehicle sector through Airbus Safran Launchers Holding (ASLH) and its wholly-owned subsidiary Airbus Safran Launchers (ASL SAS). This business combination was carried out in two stages and was finalized on June 30, 2016.

The following agreements and addenda subject to this procedure for related-party agreements were entered into in the first half of 2016:

- ASLH Agreement;
- ArianeSpace Agreement;
- Pre-emption Agreement;
- Addendum no. 6 to the Agreement dated December 21, 2004;
- Addendum to the Environmental Guarantee Agreement (EGA).

These agreements and addenda – which are being submitted for shareholder approval at this Meeting – relate to the finalization of the above-mentioned business combination. Together they make up a set of indivisible agreements that are required to set up the business combination. Primarily required by the French State to ensure the protection of national interests, they provide for the transfer of the French State’s protective rights over the strategic assets to ASLH and confer on it the benefits of the rights related to these assets.

The ASLH Agreement, ArianeSpace Agreement, Pre-emption Agreement and Addendum no. 6 to the Agreement dated December 21, 2004 were authorized by the Board of Directors on December 17, 2015. They were signed on June 24, 2016 and entered into force on June 30, 2016.

Effective from June 30, 2016, the protection of the French State’s strategic interests is ensured via:

- the ASLH Agreement: a new agreement between the French State and ASLH relating to protected assets and strategic subsidiaries and interests, entered into in the presence of Safran and Airbus SE;
- the ArianeSpace Agreement: a new agreement between the French State and ASLH relating to ArianeSpace Participation and ArianeSpace SA shares, entered into in the presence of Safran and Airbus SE.

The following agreements were entered into at the same time:

- the Pre-emption Agreement: an agreement between Safran, Airbus SE and the French State, which sets out the conditions under which Airbus SE and Safran may exercise a pre-emptive right on shares of the other partner in ASLH if the French State exercises any of the call options granted to it by Airbus SE and Safran. The French State may only buy back ASLH shares once the pre-emptive rights of Safran and Airbus SE have been used or expire;
- Addendum no. 6 to the Agreement dated December 21, 2004 entered into between Safran and the French State (described in section 7.1.4.2 of the 2016 Registration Document), whose purpose is to exclude from the scope of said Agreement the assets, subsidiaries and interests henceforth protected by the ASLH Agreement, the ArianeSpace Agreement and the Pre-emption Agreement described above.

Moreover, the EGA Addendum (an addendum to the environmental guarantee agreement with SNPE, authorized by the Board of Directors on December 17, 2015) was signed on May 17, 2016 and entered into force on June 30, 2016. Some sites transferred to ASL SAS, as part of the above-described business combination, are covered by an environmental guarantee agreement ("EGA") granted to Safran by SNPE and counter-guaranteed by the French State. With the French State’s approval, the addendum to the EGA was entered into between SNPE, ASLH and Safran in order to transfer the benefit of the EGA to ASLH for said sites (Safran being substituted by ASLH).

Shareholders are invited to approve these related-party agreements in the 6th resolution.

TEXT OF THE SIXTH RESOLUTION

Approval of related-party agreements governed by Article L.225-38 of the French Commercial Code, entered into with the French State

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the Statutory Auditors’ special report on related-party agreements governed by Article L.225-38 of the French Commercial Code, the shareholders approve the conclusions of this report and the related-party agreements entered into with the French State as described therein.

Appointments / Re-appointment of Directors

PRESENTATION OF THE 7th TO 10th RESOLUTIONS

As the terms of office of Giovanni Bisignani, Odile Desforges, Xavier Lagarde and Elisabeth Lulin are due to expire at the close of this Meeting, a number of resolutions are being put forward for the appointment or re-appointment of Directors.

Consequently, shareholders are invited to re-appoint Odile Desforges as a Director. Chair of the Audit and Risk Committee, Odile Desforges brings to the Board her experience as a Director and former senior executive of international industrial groups, as well as performance and management control expertise and acknowledged experience in purchasing, R&D projects and innovation.

Shareholders are invited to appoint Hélène Auroi Potier as a Director to replace Giovanni Bisignani. Hélène Auroi Potier would bring to the Board her experience of leading international groups, an international outlook, expertise and vision in digital technologies and transformation, as well as her experience as a director.

Shareholders are invited to appoint Patrick Pélista as a Director to replace Xavier Lagarde. Patrick Pélista would bring to the Board his experience of leading innovative, high-tech industrial groups, his experience in strategy, consulting and industrialization in the digital age.

April 24, 2017
Shareholders are invited to appoint Sophie Zurquierah as a Director to replace Elisabeth Lulin. Sophie Zurquierah would bring to the Board her experience of leading innovative, high-tech industrial equipment groups on an international scale, an international outlook, expertise in various operational and corporate positions, as well as her extensive knowledge of North America and Latin America.

If the shareholders approve these resolutions as recommended by the Board of Directors, the proportion of women on the Board will be increased to the 40% required pursuant to Article L.225-18-1 of the French Commercial Code and four independent directors will be re-appointed or appointed out of the four expiring mandates.

The profiles of the candidates put forward for appointment or re-appointment as Directors are presented in detail at the end of this report.

TEXT OF THE SEVENTH RESOLUTION

Re-appointment of Odile Desforeges as a Director

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, the shareholders re-appoint Odile Desforeges as a Director, for a four-year term expiring at the close of the Annual General Meeting to be held to approve the financial statements for the year ending December 31, 2020.

TEXT OF THE EIGHTH RESOLUTION

Appointment of Hélène Auriol Potier as a Director

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, the shareholders appoint Hélène Auriol Potier as a Director to replace Giovanni Reignani whose term of office is due to expire at the close of this Meeting.

Hélène Auriol Potier is appointed for a four-year term expiring at the close of the Annual General Meeting to be held to approve the financial statements for the year ending December 31, 2020.

TEXT OF THE NINTH RESOLUTION

Appointment of Patrick Pelata as a Director

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, the shareholders appoint Patrick Pelata as a Director to replace Xavier Lagarde whose term of office is due to expire at the close of this Meeting.

Patrick Pelata is appointed for a four-year term expiring at the close of the Annual General Meeting to be held to approve the financial statements for the year ending December 31, 2020.

TEXT OF THE TENTH RESOLUTION

Appointment of Sophie Zurquierah as a Director

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, the shareholders appoint Sophie Zurquierah as a Director to replace Elisabeth Lulin whose term of office is due to expire at the close of this Meeting.

Sophie Zurquierah is appointed for a four-year term expiring at the close of the Annual General Meeting to be held to approve the financial statements for the year ending December 31, 2020.

Advisory votes on the components of compensation due or awarded for 2016 to the executive corporate officers ("Say on Pay")

PRESENTATION OF THE 11TH AND 12TH RESOLUTIONS

In accordance with Article 26 of the November 2016 version of the AFEP-MEDEF Corporate Governance Code (hereinafter the AFEP-MEDEF Code), which Safran uses as its corporate governance framework, the Board of Directors hereby presents to shareholders the components of compensation due or awarded to each of the Company's executive corporate officers for 2016, including:

- the fixed portion;
- the annual variable portion, and where applicable, the multi-annual variable portion, with a description of the objectives used to determine this variable portion;
- exceptional compensation;
- stock options, performance shares and any other long-term compensation;
- benefits related to taking up or terminating office;
- supplementary pension plans;
- benefits-in-kind.

The AFEP-MEDEF Code recommends that this presentation be followed by a shareholder advisory vote, with separate resolutions presented for the Chairman of the Board and the Chief Executive Officer.

In accordance with these recommendations, the following two resolutions are being presented to shareholders:

- In the 11th resolution, shareholders are invited to give an advisory vote on the components of compensation due or awarded for 2016 to Ross McInnes, Chairman of the Board of Directors.

April 24, 2017
In the 12th resolution, shareholders are invited to give an advisory vote on the components of compensation due or awarded for 2016 to Philippe Petitcolin, Chief Executive Officer.

**COMPONENTS OF COMPENSATION DUE OR AWARDED TO ROSS MCINNES, CHAIRMAN OF THE BOARD OF DIRECTORS**

<table>
<thead>
<tr>
<th>Components of compensation due or awarded for 2016</th>
<th>Amounts (or accounting value) submitted to the shareholder vote</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed compensation</td>
<td>€350,000 (paid in 2016)</td>
<td>Ross McInnes’ gross annual fixed compensation was set at €350,000 by the Board of Directors at its meeting of April 23, 2015, when he was appointed as Chairman of the Board, and has remained unchanged since that date.</td>
</tr>
<tr>
<td>Annual variable compensation</td>
<td>N/A(1)</td>
<td>Ross McInnes does not receive any annual variable compensation.</td>
</tr>
<tr>
<td>Deferred variable compensation</td>
<td>N/A</td>
<td>Ross McInnes does not receive any deferred variable compensation.</td>
</tr>
<tr>
<td>Multi-year variable compensation</td>
<td>N/A</td>
<td>Ross McInnes does not receive any multi-year variable compensation.</td>
</tr>
<tr>
<td>Exceptional compensation</td>
<td>N/A</td>
<td>Ross McInnes did not receive any exceptional compensation.</td>
</tr>
<tr>
<td>Stock options, performance shares and any other long-term compensation</td>
<td>Stock options = N/A Performance shares = N/A Other long-term compensation = N/A</td>
<td>Ross McInnes does not receive any stock options. Ross McInnes does not receive any performance shares or any other long-term compensation.</td>
</tr>
<tr>
<td>Attendance fees</td>
<td>€65,000 (payable for 2016; paid in 2017)</td>
<td>Ross McInnes receives attendance fees in his capacity as a Director and Chairman of the Board of Directors, based on the allocation rules described in section 6.6.3 of the 2016 Registration Document.</td>
</tr>
<tr>
<td>Value of benefits-in-kind</td>
<td>€3,764 (accounting value)</td>
<td>Ross McInnes has the use of a company car.</td>
</tr>
</tbody>
</table>

(1) N/A = not applicable.
<table>
<thead>
<tr>
<th>Components of compensation due or awarded for 2016 that have been approved by shareholders pursuant to the procedure for related-party agreements and commitments</th>
<th>Amounts submitted to the shareholder vote</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Termination benefits</td>
<td>N/A(1)</td>
<td>Ross McInnes is not entitled to any termination benefits in his capacity as Chairman of the Board of Directors.</td>
</tr>
<tr>
<td>Non-compete indemnity</td>
<td>N/A</td>
<td>Ross McInnes is not subject to any non-compete clause.</td>
</tr>
<tr>
<td>Supplementary pension plan</td>
<td>0</td>
<td>Defined contribution supplementary pension plan:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>At its April 23, 2016 meeting, when it appointed Ross McInnes as Chairman of the Board of Directors, the Board decided to authorize him to continue to be a beneficiary under the defined contribution supplementary pension plan set up for the Group’s managerial-grade staff in France (subject to the same terms and conditions as the other plan members). Mr. McInnes was previously a beneficiary under the plan in his former capacity as a Company employee, then as Deputy Chief Executive Officer following a decision made by the Board of Directors.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The contributions to the plan are based on the compensation that Mr. McInnes receives for his role as Chairman of the Board of Directors.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The expense recorded in the 2016 financial statements relating to the contributions paid under this plan for Mr. McInnes amounted to €11,204,41.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The commitment given by the Company to enable Mr. McInnes to continue to be a beneficiary under this plan was approved at the Annual General Meeting of May 19, 2016, pursuant to the provisions of Article L.225-40 of the French Commercial Code.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>At December 31, 2016, the estimated theoretical amount(2) of the annual retirement benefits that could be paid to Ross McInnes under the defined contribution supplementary pension plan was €5,414.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Defined benefit supplementary pension plan:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>As part of the Group’s human resources management policy, on October 31, 2013, the Board of Directors decided to set up a defined benefit supplementary pension plan for Group senior managers in France, effective from January 1, 2014.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>At its April 23, 2016 meeting, the Board of Directors decided to authorize Ross McInnes to continue to be a beneficiary under the plan (subject to the same terms and conditions as the other plan members). Mr. McInnes was previously a beneficiary under the plan in his former capacity as Deputy Chief Executive Officer, following a decision by the Board of Directors.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The methods used to calculate the annual retirement benefits payable to Mr. McInnes under the plan are exactly the same as for the other plan members, namely:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the amount of the benefits will be calculated based on the average compensation over the last three years before retirement and will take into account the seniority of the beneficiary concerned within the category of top executives (hors statut) and officers (with at least five years of service), and will be equal to 1.8% of this reference compensation per year of seniority, capped at 18%;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the total replacement rate (all basic, additional and supplementary retirement benefits) is capped at 35% of the reference compensation;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the annual amount of the supplementary retirement benefits is capped at three times the annual social security ceiling in force at the date that the general social security retirement pension is paid (the applicable ceiling in 2017 is €39,226);</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the payment of these supplementary retirement benefits is subject to beneficiaries completing their careers with the Group and being entitled to retire under French social security rules having completed the required number of working years.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The potential annual retirement benefits to which Ross McInnes would be entitled under this plan, provided he meets the required conditions, would be capped at three times the annual social security ceiling, i.e. €117,684 per year based on the ceiling applicable in 2017. At December 31, 2016, the estimated theoretical amount(2) of the annual retirement benefits that could be paid to Ross McInnes under the defined benefit supplementary pension plan was €117,142.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The commitment given by the Company to enable Mr. McInnes to continue to be a beneficiary under this plan was approved at the Annual General Meeting of May 19, 2016, pursuant to the provisions of Article L.225-40 of the French Commercial Code.</td>
</tr>
</tbody>
</table>

(1) N/A = not applicable.
(2) Calculated based on the assumption that the annual retirement benefits would be received as from January 1, 2017, irrespective of the eligibility conditions (in accordance with Article D.225-104-1 of the French Commercial Code).
<table>
<thead>
<tr>
<th>Components of compensation due or awarded for 2016</th>
<th>Amounts (or accounting value) submitted to the shareholder vote</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed compensation</strong></td>
<td><strong>€600,000</strong> (paid in 2016)</td>
<td>Philippe Petticolin’s gross annual fixed compensation was set at €600,000 by the Board of Directors at its meeting of April 23, 2015, when he was appointed Chief Executive Officer, and has remained unchanged since that date.</td>
</tr>
<tr>
<td><strong>Annual variable compensation</strong></td>
<td><strong>€745,500</strong> (payable for 2016; paid in 2017)</td>
<td>At its February 24, 2016 meeting, the Board determined the methods used to calculate Philippe Petticolin’s annual variable compensation as follows:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ One-third was contingent on quantitative and qualitative individual objectives related to:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- the Group’s main industrial programs (LEAP and Silvercrest);</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- the implementation of strategic decisions made by the Board of Directors (M&amp;A transactions);</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- HR organizational measures (grading system and promotion of senior managers);</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ Two-thirds was contingent on quantitative financial performance objectives based on recurring operating income (ROI), free cash flow (FCF) and working capital.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Board set the following weightings for each of these objectives:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ROI: 60%;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- FCF: 30%;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- working capital: 10%;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The following triggering thresholds (Thresholds) applied, based on the objectives in the annual budget (Objective(s)):</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 80% of the ROI Objective;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 65% of the FCF Objective;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 135% of the working capital Objective (no variable compensation due if the level was higher than 135% for this Objective as anything over 135% corresponds to under-performance).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Philippe Petticolin’s &quot;target&quot; variable compensation, i.e., the amount payable if the achievement rate was 100% for all of the financial and individual performance objectives set out above, corresponded to 117% of his annual fixed compensation (the &quot;Target&quot;).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If Philippe Petticolin outperformed his objectives, his &quot;maximum&quot; variable compensation (i.e., the amount payable if the achievement rate was 130% for all of the financial and individual performance objectives set out above) would have corresponded to 152% of the Target, representing 152% of his annual fixed compensation (the &quot;Cap&quot;).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Calculation methods for the Thresholds and the Cap:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- The Threshold for each performance metric triggered the entitlement to variable compensation (starting at 0 from the Threshold to 100% if the budget Objective was achieved).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If an Objective was exceeded, the variable compensation allocated in respect of that Objective increased beyond 100% in proportion to the extent to which the Objective was exceeded, but capped at a maximum of 130% irrespective of the extent to which the Objective is exceeded. Consequently:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ if 130% (or more) of the ROI Objective was achieved, 130% of the Target was payable, corresponding to the Cap for this metric;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ if 130% (or more) of the FCF Objective was achieved, 130% of the Target was payable, corresponding to the Cap for this metric;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ if 65% (or less) of the working capital Objective was achieved, 130% of the Target was payable, corresponding to the Cap for this metric.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>At its February 23, 2017 meeting, based on the recommendation of the Appointments and Compensation Committee, the Board of Directors reviewed the achievement of the objectives set for the variable compensation payable to Philippe Petticolin for 2016.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Board of Directors set Philippe Petticolin’s variable compensation for 2016 at €745,500, based on the following achievement rates:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ 111% for the objective related to the Group’s financial performance, breaking down as follows:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 100% for the ROI target;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 87% for the working capital target;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 129% for the free cash flow target.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>◆ 97.5% for the individual performance objectives.</td>
</tr>
<tr>
<td><strong>Deferred variable compensation</strong></td>
<td><strong>N/A(1)</strong></td>
<td>No deferred variable compensation was awarded to Philippe Petticolin.</td>
</tr>
<tr>
<td><strong>Multi-year variable compensation</strong></td>
<td><strong>€0</strong> (no amount payable)</td>
<td>No multi-year variable compensation was awarded to Philippe Petticolin in 2016.</td>
</tr>
</tbody>
</table>

(1) NA = not applicable.

April 24, 2017

18
<table>
<thead>
<tr>
<th>Components of compensation due or awarded for 2016</th>
<th>Amounts (or present value) submitted to the shareholder vote</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exceptional compensation</td>
<td>N/A(1)</td>
<td>Philippe Petitcolin did not receive any exceptional compensation.</td>
</tr>
<tr>
<td>Stock options, performance shares and any other long-term compensation</td>
<td>Stock options = N/A</td>
<td></td>
</tr>
<tr>
<td>Performance shares = €858,780 (accounting value)</td>
<td>Philippe Petitcolin did not receive any stock options.</td>
<td></td>
</tr>
</tbody>
</table>

On the recommendation of the Appointments and Compensation Committee, at its meeting on July 28, 2016, using the authorization granted in the 23rd resolution of the May 19, 2016 Annual General Meeting, the Board of Directors decided to grant 27,380 performance shares to Philippe Petitcolin, as part of an overall performance share plan described in section 6.6.4.2 of the 2016 Registration Document.

All of the performance shares awarded to Philippe Petitcolin are subject to the same internal and external performance conditions as those applicable to the other plan beneficiaries.

The two internal performance conditions count for 70% of the total vested shares and are based on:
- ROI, for 35%;
- FCF, for 35%.

The achievement levels for these conditions are measured by reference to the average of the targets for ROI and FCF set for the fiscal year in which the grant takes place and for the following two fiscal years, as contained in the most recent medium-term plan (MTP) approved by the Board of Directors before the grant date. The following achievement levels have been set for these conditions:
  - lowest achievement level: if 80% of the MTP target is achieved, 40% of the shares contingent on that target will vest;
  - target achievement level: if 100% of the MTP target is achieved, 80% of the shares contingent on that target will vest;
  - highest achievement level (cap): if 125% of the MTP target is achieved, 100% of the shares contingent on that target will vest;
  - between the lowest achievement level and the target level, and between the target level and the highest achievement level, the number of shares that will vest will vary in linear fashion. Below the lowest achievement level, none of the shares contingent on the internal performance condition concerned will vest.

The external performance condition counts for 30% of the total vested shares and is based on Safran’s total shareholder return (TSR) performance as measured relative to a panel of peer companies operating in the same business sectors as Safran (Aerospace, Defense and Security)(2).

The following achievement levels have been set for this condition:
- lowest achievement level: if Safran’s TSR is equal to that of the peer companies, 40% of the shares contingent on the external performance condition will vest;
- target achievement level: if Safran’s TSR is 8 points higher than that of the peer companies, 80% of the shares contingent on the external performance condition will vest;
- highest achievement level: if Safran’s TSR is 12 points higher than that of the peer companies, 100% of the shares contingent on the external performance condition will vest.
- between the lowest achievement level and the target level, and between the target level and the highest achievement level, the number of shares that will vest will vary in linear fashion. Below the lowest achievement level, none of the shares contingent on the external performance condition will vest.

Under the rules of the performance share plan, the shares will only vest if the beneficiary still forms part of the Group on the vesting date, apart from in a limited number of cases (death, disability, retirement of the beneficiary or a specific decision by the Board of Directors).

The vesting period has been set at three years (2016-2018) and the number of shares that will ultimately vest will depend on the extent to which the applicable performance conditions are met over that period.

The vesting period will be followed by a one-year lock-up period.

The Board has decided that following this lock-up period and until his term of office ends, Philippe Petitcolin will be required to hold in registered form 40% of the vested performance shares granted under this plan and any future plans, until the number of shares he holds represents the equivalent of one year of his most recent annual fixed compensation.

In addition, Philippe Petitcolin has given a formal undertaking to refrain from using instruments to hedge the risks related to these shares until after the end of the lock-up period.

The accounting value of these performance shares has been estimated at €858,780(3).

<table>
<thead>
<tr>
<th>Other long-term compensation</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philippe Petitcolin did not receive any other long-term compensation.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Attendance fees</th>
<th>€38,500 (payable for 2016; paid in 2017)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philippe Petitcolin receives attendance fees in his capacity as a Director of the Company, in accordance with the allocation rules described in section 6.6.3 of the 2016 Registration Document.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Value of benefits-in-kind</th>
<th>€4,011 (accounting value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philippe Petitcolin has the use of a company car.</td>
<td></td>
</tr>
</tbody>
</table>

---

(1) N/A = not applicable.
(2) At the grant date, these companies comprised Airbus, BAE Systems, Boeing, Finmeccanica, MTU Aero Engines, Rolls-Royce, Thales, Gemalto and Zodiac Aerospace, but the latter two companies have subsequently been removed.
(3) In accordance with IFRS 2, the value of the performance shares was measured at the grant date and not based on compensation received by the beneficiary during the year (see Note 1.4 in section 3.1 of the 2016 Registration Document).
<table>
<thead>
<tr>
<th>Components of compensation due or awarded for 2016 that have been approved by shareholders pursuant to the procedure for related-party agreements and commitments</th>
<th>Amounts submitted to the shareholder vote</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Termination benefits</td>
<td>N/A(^{(1)})</td>
<td>Philippe Pettelin is not entitled to any termination benefits in his capacity as Chief Executive Officer.</td>
</tr>
<tr>
<td>Non-compete indemnity</td>
<td>N/A</td>
<td>Philippe Pettelin is not subject to any non-compete clause.</td>
</tr>
<tr>
<td>Supplementary pension plan</td>
<td>€0</td>
<td><strong>Defined contribution supplementary pension plan:</strong> At its April 23, 2015 meeting, when it appointed Philippe Pettelin as Chief Executive Officer, the Board of Directors decided to authorize him to continue to be a beneficiary under the defined contribution supplementary pension plan set up for the Group’s managerial-grade staff (subject to the same terms and conditions as the other plan members). Mr. Pettelin was previously a beneficiary under the plan in his former capacity as a Company employee. The contributions to the plan are based on the annual compensation (fixed and variable) that Mr. Pettelin receives for his role as Chief Executive Officer. The expense recorded in the 2016 financial statements relating to the contributions paid under the plan for Mr. Pettelin amounted to €40,175.66. The commitment given by the Company to enable Mr. Pettelin to continue to be a beneficiary under this plan (subject to the same terms and conditions as the other plan members). Mr. Pettelin was previously a beneficiary under the plan in his former capacity as a Company employee. The methods used to calculate the annual retirement benefits payable to Mr. Pettelin under the plan are the same as those for the other plan members, namely: - the amount of the benefits will be calculated based on the average compensation over the last three years before retirement and will take into account the seniority of the beneficiary concerned within the category of top executives (hors statut) and officers (with at least five years of service), and will be equal to 1.6% of this reference compensation per year of seniority, capped at 18%; - the total replacement rate (all basic, additional and supplementary retirement benefits) is capped at 35% of the reference compensation; - the annual amount of the supplementary retirement benefits is capped at three times the annual social security ceiling in force at the date that the general social security retirement pension is paid (the applicable ceiling in 2017 is €29,325); - the payment of these supplementary retirement benefits is subject to beneficiaries completing their careers with the Group and being entitled to retire under French social security rules having completed the required number of working years. The potential annual retirement benefits to which Philippe Pettelin would be entitled under this plan, provided he meets the required conditions, would be capped at three times the annual social security ceiling, i.e., €177,684 per year based on the ceiling applicable in 2017. At December 31, 2016, the estimated theoretical amount(^{(2)}) of the annual retirement benefits that could be paid to him corresponded to this ceiling. The commitment given by the Company to enable Mr. Pettelin to continue to be a beneficiary under this plan was approved at the Annual General Meeting of May 19, 2016, pursuant to the provisions of Article L.225-40 of the French Commercial Code.</td>
</tr>
<tr>
<td>(1) N/A = not applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Calculated based on the assumption that the annual retirement benefits would be received as from January 1, 2017, irrespective of the eligibility conditions (in accordance with Article D.225-104-1 of the French Commercial Code).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

April 24, 2017
TEXT OF THE ELEVENTH RESOLUTION

Advisory vote on the components of compensation due or awarded for 2016 to Ross McInnes, Chairman of the Board of Directors

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, and having been consulted in application of the "say-on-pay" recommendations in Article 26 of the AFEP-MEDEF Code on Corporate Governance – which the Company uses as its reference framework for corporate governance in accordance with Article L.225-37 of the French Commercial Code – the shareholders issue a positive advisory vote on the components of compensation due or awarded for 2016 to Ross McInnes (Chairman of the Board of Directors), as presented in section 6.6.2.3. of the 2016 Registration Document and in the report of the Board of Directors on the resolutions proposed at this Annual General Meeting.

TEXT OF THE TWELFTH RESOLUTION

Advisory vote on the components of compensation due or awarded for 2016 to Philippe Petitcolin, Chief Executive Officer

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, and having been consulted in application of the "say-on-pay" recommendations in Article 26 of the AFEP-MEDEF Code on Corporate Governance – which the Company uses as its reference framework for corporate governance in accordance with Article L.225-37 of the French Commercial Code – the shareholders issue a positive advisory vote on the components of compensation due or awarded for 2016 to Philippe Petitcolin (Chief Executive Officer), as presented in section 6.6.2.3. of the 2016 Registration Document and in the report of the Board of Directors on the resolutions proposed at this Annual General Meeting.

Compensation policy

PRESENTATION OF THE 13th AND 14th RESOLUTIONS

In accordance with Article L. 225-37-2 of the French Commercial Code, each year the shareholders are asked to give a forward-looking ("ex-ante") vote on the principles and criteria used to determine, allocate and award the fixed, variable and exceptional components of the total compensation and benefits packages of executive corporate officers. Consequently, the shareholders are invited for the first time to vote on the compensation policy adopted by the Board of Directors, in accordance with the new requirements introduced by French Act 2016-1691 of December 9, 2016 relating to transparency, anti-corruption measures and modernization of the economy.

These principles and criteria adopted by the Board of Directors form the Company’s compensation policy and are presented in section 6.6.1 of the 2016 Registration Document.

As from 2018, shareholders will be asked to give a backward-looking ("ex-post") vote on the components of the compensation and benefits packages of executive corporate officers set by the Board for 2017 based on the compensation policy voted on in the 13th and 14th resolutions of this Meeting.

In addition, payment of the variable and any exceptional components of the executive corporate officers’ compensation for 2017 will be subject to shareholder approval at the 2018 Annual General Meeting.

In the 13th and 14th resolutions, you are invited to vote in favor of the compensation policy applicable to the Chairman of the Board of Directors and the Chief Executive Officer respectively.

TEXT OF THE THIRTEENTH RESOLUTION

Approval of the compensation policy applicable to the Chairman of the Board of Directors

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the Board of Directors’ report on the compensation policy applicable to executive corporate officers drawn up in accordance with Article L.225-37-2 of the French Commercial Code, the shareholders approve the compensation policy applicable to the Chairman of the Board of Directors, as presented in sections 6.6.1 and 6.6.1.1 of the 2016 Registration Document.

TEXT OF THE FOURTEENTH RESOLUTION

Approval of the compensation policy applicable to the Chief Executive Officer

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the Board of Directors’ report on the compensation policy applicable to executive corporate officers drawn up in accordance with Article L.225-37-2 of the French Commercial Code, the shareholders approve the compensation policy applicable to the Chief Executive Officer, as presented in sections 6.6.1 and 6.6.1.2 of the 2016 Registration Document.

April 24, 2017 21
Authorization for the Board of Directors to carry out a share buyback program

PRESENTATION OF THE 15TH RESOLUTION

Share buyback programs
The Company needs to have the necessary flexibility to react to changes in financial markets by buying back Safran shares. Shareholders are therefore invited to renew the authorization given to the Board of Directors to carry out a share buyback program, with the following main conditions:

- The number of shares that may be bought back may not exceed 10% of the Company's total outstanding shares (for information purposes, 41,702,958 shares based on the issued capital at December 31, 2016) and the Company may at no time directly or indirectly hold a number of Safran shares representing more than 10% of its capital.
- The shares may be purchased, sold or transferred by any authorized method, including through block trades for all or some of the program, subject to the regulations in force at the date on which the authorization is implemented.

Subject to the limits authorized by the applicable laws and regulations, the Board of Directors may use this authorization at any time, except during periods when there is a public offer in progress for the Company's shares, or during the run-up to such an offer.

The maximum per-share purchase price of shares acquired using this authorization would be set at €95 and the maximum total investment in the buyback program would be €3.9 billion (in lieu of the amounts set out in section 7.2.7.2 of the 2016 Registration Document).

The buyback program would be used to purchase shares for the following purposes:
- to maintain a liquid market in the Company's shares via a liquidity agreement entered into with an investment services firm;
- for allocation or sale to employees and/or certain corporate officers, notably in connection with a profit-sharing plan, free share grant plan or Group employee savings plan;
- for delivery on the exercise of rights attached to securities redeemable, convertible, exchangeable or otherwise exercisable for shares of the Company;
- for delivery in payment or exchange for external growth transactions; and
- for cancellation, pursuant to the share capital reduction authorization in effect, granted by the Annual General Meeting.

This program is also designed to enable any future market practices permitted by the AMF to be carried out and, more generally, to enable any other authorized operations or operations that would be authorized in the future by the applicable regulations. In such a case, the Company will inform its shareholders in a press release.

This authorization would be given for a period of 18 months and would supersede the previous authorization granted for the same purpose in the 21st resolution of the Annual General Meeting held on May 19, 2016.

Report on the utilization in 2016 of previous shareholder-approved share buyback programs
In 2016, the aggregate number of shares purchased under the liquidity agreement entered into with Oddo Corporate Finance amounted to 2,645,456.

The total number of shares sold under this liquidity agreement during the year amounted to 2,634,148.

No treasury shares purchased under a buyback program were canceled in 2016.

During 2016 the Company carried out the following transactions in its own shares:

- On November 21, 2016 it bought back 600,000 Safran shares. These shares were purchased for subsequent grants or sales to employees and/or corporate officers of the Company or other Group companies.
- On December 12, 2016, Safran announced its intention to buy back up to €450 million worth of its own shares in order to neutralize the dilutive effect of equity instruments on its balance sheet. On December 8, 2016, Safran signed a share purchase agreement with an investment services firm for an initial buyback tranche (see section 7.2.7 of the 2016 Registration Document). The buyback of this first tranche was carried out in two phases with the first buyback of 621,475 shares completed on December 30, 2016. These shares are earmarked to cover exchangeable debt securities.

At December 31, 2016, Safran directly held 1,838,487 of its own shares, representing 0.44% of its capital.

These treasury shares were held for the following purposes:
- for allocation or sale to employees: 1,116,604 shares, representing 0.27% of the Company's capital;
- to cover exchangeable debt securities: 621,475 shares, representing 0.15% of the Company's capital;
- to maintain a liquid market in the Company's shares via a liquidity agreement: 98,418 shares, representing 0.02% of the Company's capital.

TEXT OF THE FIFTEENTH RESOLUTION

Authorization for the Board of Directors to carry out a share buyback program

Deliberating in accordance with the rules of quorum and majority applicable to Ordinary General Meetings and having considered the report of the Board of Directors, the shareholders grant the Board of Directors an authorization – which may be delegated pursuant to the law – to purchase, directly or indirectly, the Company's shares in accordance with the conditions set out in Articles L.225-209 et seq. of the French Commercial Code and EC Regulation 596/2014 dated April 16, 2014, as well as any other laws and regulations that may be applicable in the future.

April 24, 2017
The authorization may be used to purchase shares:
- to maintain a liquid market in the Company’s shares via a liquidity agreement that complies with the Code of Ethics drawn up by the French association of financial and investment firms (Association Française des Marchés Financiers – AMAFI), approved by the AMF, and entered into with an investment services firm;
- for allocation or sale to employees and/or corporate officers of the Company or other Group companies, in accordance with the terms and conditions provided for by law, notably in connection with a profit-sharing plan, free share grants, the exercising of stock options, the Group employee savings plan, or any company employee savings plan in place within the Group;
- for delivery on the exercise of rights attached to securities redeemable, convertible, exchangeable or otherwise exercisable for shares of the Company;
- to hold in treasury for subsequent delivery in payment or exchange for external growth transactions; and
- for cancellation, pursuant to the share capital reduction authorization in effect, granted by the Annual General Meeting.

This authorization is also designed to enable any future market practices permitted by the AMF to be carried out and, more generally, to enable any other operations authorized by the applicable regulations. The Company will inform its shareholders in a press release prior to carrying out any such operations.

Shares may be purchased, sold, or transferred by any method allowed under the laws and regulations applicable at the transaction date, on one or more occasions, including, in accordance with the regulations in force at the date of this Meeting, over-the-counter and through block trades for all or part of the program, as well as through the use of derivative financial instruments.

The Board of Directors may use this authorization at any time subject to the limitations set down by the applicable laws and regulations, except during, or in the run-up to, a public offer for the Company’s shares.

The number of shares that may be bought back under this authorization may not exceed 10% of the Company’s total outstanding shares (for information purposes, 4,173,958 shares based on the issued capital at December 31, 2016). This ceiling is reduced to 5% for shares acquired for the purpose of being held in treasury for subsequent delivery in payment or exchange for external growth transactions. When shares are bought back for the purpose of maintaining a liquid market in the Company’s shares via a liquidity agreement, the number of shares included in the calculation of the 10% ceiling corresponds to the number of shares purchased less any shares sold during the period covered by this authorization.

Under no circumstances may the Company hold, either directly or indirectly, more than 10% of its share capital.

The shares may not be purchased at a price of more than €95 per share and the maximum amount that may be invested in the program is €3.9 billion. However, the Board of Directors may adjust this maximum purchase price to take into account the impact on the share price of any corporate actions.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to carry out this share buyback program, set the applicable terms and conditions, make the required adjustments as a result of any corporate actions, place any and all buy and sell orders, enter into any and all agreements notably for the keeping of registers of share purchases and sales, make any and all filings with the AMF and any other organization, carry out all other formalities, and generally do everything necessary to use this authorization.

This authorization is given for a period of 18 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 21st resolution of the Annual General Meeting held on May 19, 2010.

EXTRAORDINARY RESOLUTIONS

Amendment to the Company’s bylaws

PRESENTATION OF THE 16TH RESOLUTION

In the 16th resolution shareholders are invited to amend the Company’s bylaws in order to raise the age limit for serving as Chief Executive Officer or Deputy Chief Executive Officer (if applicable) from 65 to 68.

This resolution is being submitted because the age limit of 65 for these posts no longer seems suited to the Company in view of executives’ longer careers. By extending the age limit to 68, the Company will be able to benefit from the experience and expertise of high-quality executives for a longer period of time. Many of Safran’s peer companies offer such a possibility in their bylaws, and the Board of Directors considers that the higher age limit would be in Safran’s best interests.

In view of the strategic, industrial and operational challenges facing Safran in the coming years, including the ramp-up of the LEAP program, this amendment to the bylaws would enable the Board of Directors (if it so decides) to extend Philippe Petitcolin’s term of office, which is due to expire at the Annual General Meeting to be held to approve the financial statements for the year ending December 31, 2017.

TEXT OF THE SIXTEENTH RESOLUTION

Amendment to Article 25 of the Company’s bylaws in order to raise the age limit for serving as Chief Executive Officer or Deputy Chief Executive Officer to 68

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors, the shareholders resolve:

- to raise the age limit for serving as Chief Executive Officer or Deputy Chief Executive Officer to 68;

April 24, 2017
• to accordingly amend Article 25 of the Company’s bylaws to read as follows:

"Article 25 – Age Limit

25.1 The age limit for holding office as Chief Executive Officer or Deputy Chief Executive Officer shall be sixty-eight.

25.2 No-one over the age of sixty-eight may be appointed as Chief Executive Officer or Deputy Chief Executive Officer.

25.3 When the Chief Executive Officer or a Deputy Chief Executive Officer reaches the age of sixty-eight during his term of office, he will be deemed to have resigned from his position at the close of the first Annual General Meeting held after the date of his sixty-eighth birthday."

Financial authorizations

Safran needs to have the flexibility required to raise financing swiftly to support its ongoing operations and business development, based on opportunities arising in financial markets and using the most suitable financial instruments. To this end shareholders are invited to grant the Board of Directors the necessary authorizations to issue ordinary shares and/or securities carrying immediate or deferred rights to shares of the Company.

The Board of Directors is seeking these authorizations in order to carry out the operations considered necessary for the effective running and future growth of the Company and the Group. If the new authorizations are adopted, they will supersede the previous authorizations granted to the Board of Directors for the same purpose.

In order to take into consideration the diversity and expectations of shareholders, two sets of financial authorizations are being submitted to the shareholders for their approval:

- a first set of authorizations which may not be used during, or in the run-up to, a public offer for the Company’s shares;
- a second set of authorizations which may only be used during, or in the run-up to, a public offer for the Company’s shares.

A summary table is provided at the end of this report setting out the financial authorizations that shareholders are being asked to approve.

Ceilings

The authorizations given in these resolutions would enable the Board of Directors to increase the Company’s capital by a maximum nominal amount of €20 million (blanket ceiling set in the 17th resolution), corresponding to a maximum of 100 million shares and representing less than 25% of the current capital.

The following individual ceilings provided for in the various resolutions are included in this blanket ceiling (expressed in terms of nominal value):

**Resolutions that may not be used during, or in the run-up to, a public offer for the Company’s shares**

- €20 million ceiling applicable to capital increases carried out with pre-emptive subscription rights for existing shareholders (17th resolution);
- €8 million ceiling (less than 10% of the Company’s capital) applicable to capital increases carried out without pre-emptive subscription rights for existing shareholders, by way of a public offer (18th resolution);
- €8 million ceiling applicable to capital increases carried out without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company (19th resolution);
- €8 million ceiling applicable to capital increases carried out without pre-emptive subscription rights for existing shareholders, through a private placement (20th resolution);
- ceiling currently equal to 15% of any issues carried out pursuant to the 17th to 20th resolutions which are oversubscribed (21st resolution), also subject to the ceiling applicable in the relevant resolution;
- €12.5 million ceiling applicable to capital increases carried out by capitalizing reserves (22nd resolution).

**Resolutions that may only be used during, or in the run-up to, a public offer for the Company’s shares**

- €8 million ceiling applicable to capital increases carried out with pre-emptive subscription rights for existing shareholders (23rd resolution);
- €5 million ceiling (less than 10% of the Company’s capital) applicable to capital increases carried out without pre-emptive subscription rights for existing shareholders, by way of a public offer (24th resolution);
- €8 million ceiling applicable to capital increases carried out without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company (25th resolution);
- €8 million ceiling applicable to capital increases carried out without pre-emptive subscription rights for existing shareholders, through a private placement (20th resolution);
- ceiling currently equal to 15% of any issues carried out pursuant to the 23rd to 26th resolutions which are oversubscribed, also subject to the ceiling applicable in the relevant resolution (27th resolution);
- €8 million ceiling applicable to capital increases carried out by capitalizing reserves (28th resolution).

The blanket ceiling set in the 17th resolution also includes any capital increases carried out as a result of employee share issues, which are capped at 1% of the Company’s capital (29th resolution).

None of the above ceilings include the par value of any additional shares that may be issued in the event of further corporate actions, in accordance with the applicable laws and regulations and any contractual provisions, to protect the rights of existing holders of securities carrying rights to the Company’s shares or beneficiaries of free share grants.

If the authorizations granted in the 17th to 21st and 23rd to 27th resolutions are used to issue debt securities, the aggregate nominal amount of said debt securities may not exceed €2 billion (or the equivalent of this amount for issues denominated in foreign currency or a monetary unit determined by reference to a basket of currencies).

**Sub-ceilings applicable to issues carried out without pre-emptive subscription rights for existing shareholders**

Issues carried out without pre-emptive subscription rights for existing shareholders (pursuant to the 16th to 21st resolutions and the 24th to 27th resolutions) are
subject to a cumulative sub-ceiling of €8 million for capital increases (less than 10% of the share capital) and €1.8 billion for issues of debt securities (irrespective of whether or not the issues are carried out during, or in the run-up to, a public offer for the Company’s shares).

**Sub-ceiling applicable to capital increases carried out during, or in the run-up to, a public offer for the Company’s shares**

All capital increases that may be carried out during, or in the run-up to, a public offer for the Company’s shares, either with or without pre-emptive subscription rights for existing shareholders (pursuant to the 23rd to 28th resolutions), are subject to an aggregate ceiling of €8 million (less than 10% of the capital).

**Use of previous authorizations**

The financial authorizations given to the Board of Directors at the April 23, 2015 and May 19, 2016 Annual General Meetings were used as follows:

- The authorization given to the Board of Directors in the 21st resolution of the April 23, 2015 Annual General Meeting to increase the Company’s capital through a private placement was used in January 2016 to issue bonds convertible and/or exchangeable for new and/or existing shares (“OCEANE” bonds) (see section 7.2.3.2 of the 2016 Registration Document).

- The authorization given to the Board of Directors in the 23rd resolution of the May 19, 2016 Annual General Meeting to grant new or existing shares of the Company free of consideration was used in July 2016 and March 2017 (see section 7.3.7.1 of the 2016 Registration Document).

The other authorizations given to the Board of Directors by shareholders in order to increase the Company’s capital were not used in 2016.

**Authorizations which may not be used during, or in the run-up to, a public offer for the Company’s shares**

**PRESENTATION OF THE 17TH RESOLUTION**

**Issue of various shares and/or other securities with pre-emptive subscription rights**

The purpose of the 17th resolution is to authorize the Board of Directors to issue ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders. The pre-emptive rights granted to existing shareholders may be detached from the shares to which they relate and may be transferred or traded throughout the subscription period of any issues carried out under this authorization.

These pre-emptive subscription rights would entitle their holders to subscribe for a number of new shares proportionate to the number of pre-emptive rights held, during a period corresponding to at least five trading days from the opening of the subscription period.

The Board of Directors would be able to use this authorization at any time except during, or in the run-up to, a public offer for the Company’s shares.

The maximum aggregate nominal amount of any capital increases carried out pursuant to this resolution – either immediately or on the exercise of rights to shares of the Company – would be set at €20 million (representing approximately 24% of the Company’s capital). This €20 million ceiling corresponds to a blanket ceiling covering all of the capital increases that may be carried out pursuant to this resolution as well as the 16th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th and 29th resolutions.

The maximum principal amount of any debt securities issued would be set at €2 billion. The nominal amount of any capital increases resulting from the exercise of rights attached to debt securities carrying rights to shares of the Company would be included in the €20 million blanket ceiling on capital increases set in this resolution. This €2 billion ceiling corresponds to a blanket ceiling covering the principal amount of all debt securities that may be issued pursuant to this resolution as well as the 16th, 19th, 20th, 21st, 23rd, 24th, 25th, 26th and 27th resolutions.

This authorization would supersede, as from the date of the Meeting, the authorization granted to the Board of Directors for the same purpose in the 18th resolution of the Annual General Meeting held on April 23, 2015.

**TEXT OF THE SEVENTEENTH RESOLUTION**

**Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders, which may not be used during, or in the run-up to, a public offer for the Company’s shares**

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors’ special report, in accordance with the applicable laws and regulations, and in particular Articles L.225-129-2, L.225-132 and L.228-91 et seq. of the French Commercial Code, and having noted that the share capital has been fully paid up, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company’s capital by issuing, on one or more occasions, ordinary shares and/or securities carrying immediate or deferred rights to new or existing ordinary shares of the Company (either with or without consideration), with pre-emptive subscription rights for existing shareholders. The Board will have full discretionary powers to determine the amount and timing of said issue(s), which may be carried out in France or abroad and may be denominated in euros, foreign currency or a monetary unit determined by reference to a basket of currencies.

   However, if a third party launches a public offer for the Company’s shares, the Board may not use this authorization during, or in the run-up to, the offer, unless it obtains the prior approval of the shareholders in a General Meeting.

2. Resolve that if the Board of Directors uses this authorization:

   - The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization – either directly and/or on the exercise of rights to shares – is set at €20 million corresponding to 100 million shares. This €20 million ceiling represents a blanket ceiling covering all of the capital increases that may be carried out under this authorization and the authorizations granted in the 16th, 19th, 20th, 21st, 23rd, 24th, 25th, 26th, 27th, 28th and
29th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However, it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company’s shares.

- The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €2 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This ceiling represents a blanket ceiling covering the principal amount of all debt securities that may be issued under this authorization and the authorizations granted in the 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th and 27th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However, it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

3. Resolve that existing shareholders will have pre-emptive rights to subscribe for the securities issued pursuant to this authorization, in proportion to their existing holdings.

4. Note that in accordance with the law, the Board of Directors may grant shareholders additional pre-emptive rights to subscribe for any securities not taken up by other shareholders exercising their pre-emptive subscription rights. Such additional rights will also be exercisable in proportion to shareholders’ existing holdings and within the limits of their requests.

5. Resolve that if an issue is not taken up in full by shareholders exercising their pre-emptive rights as described above, the Board of Directors may take one or more of the following courses of action, in accordance with the law and in the order of its choice:
   - limit the amount of the issue to the subscriptions received, provided that at least three-quarters of the issue is taken up;
   - freely allocate all or some of the unsubscribed securities;
   - offer some or all of the unsubscribed securities on the open market, either in France or abroad.

6. Resolve that Safran stock warrants may be offered for subscription on the above basis or allocated without consideration to existing shareholders. In the latter case the Board of Directors will have full powers to decide that rights to fractions of warrants will not be transferable or tradable and that the corresponding warrants will be sold.

7. Resolve that the Board of Directors may suspend the exercise of rights to shares of the Company for a maximum period of three months, and make any adjustments in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company’s shares.

8. Note that in the event of an issue of securities carrying rights to shares of the Company, this authorization automatically entails the waiver by shareholders of their pre-emptive rights to subscribe for any shares to be issued on the exercise of the rights attached to said securities.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to:

- use this authorization and notably to determine the timing, characteristics and other terms and conditions of any issues carried out, including the type and form of securities to be issued, the start and end dates of the subscription period, the issue price and cum-rights date of the issued securities, the method by which the securities will be paid up, and the terms and conditions for exercising the rights attached to securities carrying rights to shares of the Company;
- charge the issuance costs against the related premiums and deduct from the premiums the amounts necessary to raise the legal reserve to the required level;
- in the case of the issuance of debt securities, determine (i) whether the debt should be subordinated or unsubordinated (and the ranking of any subordinated debt), (ii) the interest rate, (iii) the life of the securities (i.e. dated or undated), (iv) their redemption price (which may be fixed or variable and with or without a premium) and repayment terms, depending on market conditions, (v) the terms of their exercise for shares of the Company, and (vi) any other terms and conditions of the issue, including any collateral or other form of guarantee, as well as to amend any of said terms and conditions during the life of the securities concerned;
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s), place on record the capital increase(s), amend the Company’s bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 18th resolution of the Annual General Meeting held on April 23, 2015.
PRESENTATION OF THE 18TH TO 20TH RESOLUTIONS

Issue of shares and/or other securities without pre-emptive subscription rights

The purpose of the 18th to 20th resolutions is to authorize the Board of Directors to issue ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders.

The Board of Directors would be able to use these authorizations at any time except during, or in the run-up to, a public offer for the Company's shares.

The maximum nominal amount of any capital increases carried out using these three authorizations (both per authorization and cumulatively) would be set at €8 million, representing approximately 9.6% of the Company's capital. The amounts used under these authorizations would be included in the blanket ceiling set in the 17th resolution.

The maximum principal amount of any debt securities issued would be set (both per authorization and cumulatively) for the three authorizations, at €1.8 billion. The amounts used under these authorizations would be included in the €2 billion blanket ceiling set in the 17th resolution. The nominal amount of any capital increases resulting from the exercise of rights attached to debt securities carrying rights to shares of the Company would be included in the €8 million individual and cumulative ceiling set in the 16th to 20th resolutions (and therefore in the blanket ceiling set in the 17th resolution).

These authorizations would supersede, as from the date of this Meeting, the authorization granted to the Board of Directors for the same purpose in the 19th, 20th and 21st resolutions of the Annual General Meeting held on April 29, 2015.

18th resolution (public offers). In this resolution the Board is seeking an authorization to issue ordinary shares and/or securities carrying rights to shares of the Company, by way of a public offer. If this resolution is adopted, the Board of Directors would be able to grant shareholders a priority subscription right for a period of at least three trading days but this right would be non-transferable and non-transferable. The waiver of shareholders' pre-emptive subscription rights would make it easier to carry out public offers, especially when an issue has to be organized swiftly in order for it to be successful, or when shares or other securities are offered in financial markets both in France and abroad.

19th resolution (issues carried out in the event of a public exchange offer initiated by the Company). The purpose of this resolution is to authorize the Board to issue shares of the Company and/or securities carrying rights to the Company's shares as payment for securities of another company that are tendered to a public exchange offer initiated by the Company in France or abroad.

20th resolution (private placements governed by Article L.411-2-III of the French Monetary and Financial Code). This resolution would authorize the Board of Directors to issue shares and/or securities carrying rights to the Company's shares, by way of a private placement carried out through an offer to qualified investors or a restricted group of investors. The simplified procedure for this type of private placement would enable the Company to react swiftly to market opportunities and rapidly raise the funds it requires.

TEXT OF THE EIGHTEENTH RESOLUTION

Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company without pre-emptive subscription rights for existing shareholders, by way of a public offer, which may not be used during, or in the run-up to, a public offer for the Company's shares

Delegating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors' special report, in accordance with the applicable laws and regulations and in particular Articles L.225-129 et seq. of the French Commercial Code, notably Articles L.225-129-2, L.226-135 and L.226-136 as well as Articles L.228-91 et seq. of said Code, and having noted that the share capital has been fully paid up, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company's capital by issuing, on one or more occasions and through a public offer, ordinary shares of the Company and/or securities carrying immediate or deferred rights to new or existing ordinary shares of the Company (either with or without consideration). The Board will have full discretionary powers to determine the amount and timing of said issue(s), which may be carried out in France or abroad and may be denominated in euros, foreign currency or a monetary unit determined by reference to a basket of currencies.

However, if a third party launches a public offer for the Company's shares, the Board may not use this authorization during, or in the run-up to, the offer, unless it obtains the prior approval of the shareholders in a General Meeting.

2. Resolve that if the Board of Directors uses this authorization:

   - The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization – either directly or on the exercise of rights to shares – is set at €8 million. This €8 million ceiling (i) represents an overall ceiling on the nominal amount of the capital increases that may be carried out under this authorization and the authorizations granted in the 19th, 20th, 21st, 24th, 25th, 26th and 27th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization), and (ii) is included in the blanket ceiling set in the 17th resolution (or in any ceiling set in a resolution with the same purpose that could supersede the 17th resolution during the validity period of this authorization). However, it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company's shares.

   - The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €1.8 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This €1.8 billion ceiling (i) represents an overall ceiling on the principal amount of debt securities that may be issued under this authorization and the authorizations granted in the 19th, 20th, 21st, 24th, 25th, 26th and 27th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization), and (ii) is included in the blanket ceiling set in the 17th resolution (or in any ceiling set in a resolution with the same purpose that could supersede the 17th resolution during the validity period of this authorization). However, it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

April 24, 2017
For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

3. Resolve to waive shareholders' pre-emptive rights to subscribe for the shares and/or other securities to be issued under this authorization. However, in accordance with paragraph 5 of Article L.225-135 and Article R.226-131 of the French Commercial Code, the Board of Directors may offer existing shareholders a priority right to subscribe for all or part of any issue(s) carried out under this authorization for a period of no less than three trading days. Such priority rights will not be transferable or tradable and will be exercisable in proportion to shareholders' existing interests.

4. Resolve that if an issue is not taken up in full (including by shareholders exercising their above-mentioned priority rights), the Board of Directors may take one or the other of the following courses of action, in accordance with the law and in the order of its choice:
   - limit the amount of the issue to the subscriptions received, provided that at least three-quarters of the issue is taken up;
   - freely allocate all or some of the unsubscribed securities.

5. Note that in the event of an issue of securities carrying rights to shares of the Company, this authorization automatically entails the waiver by shareholders of their pre-emptive rights to subscribe for any shares to be issued on the exercise of the rights attached to said securities.

6. Resolve that the issue price of the shares or securities carrying rights to shares will be at least equal to the minimum price provided for in the laws and regulations in force on the issue date (for information purposes, corresponding at the date of this Meeting to a price at least equal to the weighted average of the prices quoted for the Company's shares over the three trading days preceding the pricing date, less a discount of no more than 5%).

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to:

- use this authorization and notably to determine the timing, characteristics and other terms and conditions of any issues carried out, including the type and form of securities to be issued, the start and end dates of the subscription period, the issue price and cum-dividends date of the issued securities, the method by which the securities will be paid up, and the terms and conditions for exercising the rights attached to securities carrying rights to shares of the Company;
- suspend, where appropriate, the exercise of any rights attached to new or existing securities in accordance with the applicable laws and regulations, and make any adjustments in order to take into account the impact of any issues on the Company's capital and set the terms and conditions for protecting the rights of holders of securities carrying rights to the Company's shares, in accordance with the applicable laws, regulations and contractual provisions;
- in the case of the issuance of debt securities, determine (i) whether the debt will be subordinated or unsubordinated (and the ranking of any subordinated debt), (ii) the interest rate, (iii) the life of the securities (i.e. dated or undated), (iv) their redemption price (which may be fixed or variable and with or without a premium) and repayment terms, depending on market conditions, (v) the terms of their exercise for shares of the Company, and (vi) any other terms and conditions of the issue, including any collateral or other form of guarantee, as well as to amend any of said terms and conditions during the life of the securities concerned;
- charge the issuance costs against the related premiums and deduct from the premiums the amounts necessary to raise the legal reserve to the required level; and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s), place on record the capital increase(s), amend the Company's bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 18th resolution of the Annual General Meeting held on April 23, 2016.

TEXT OF THE NINETEENTH RESOLUTION

Authorization for the Board of Directors to issue shares and/or securities carrying rights to shares of the Company, without preemptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company, which may not be used during, or in the run-up to, a public offer for the Company's shares

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors' special report, in accordance with the applicable laws and regulations and in particular Articles L.225-129-2 to L.225-129-6, L.225-148 and L.226-91 et seq. of the French Commercial Code, the shareholders:

1. Authorize the Board of Directors to issue shares of the Company and/or securities carrying immediate or deferred rights to the Company's shares as payment for securities of another company tendered to a public exchange offer initiated by the Company. The shareholders further authorize the Board to cancel the pre-emptive rights of existing shareholders to subscribe for the shares and/or other securities issued under this authorization.

   This authorization may be used in connection with any public exchange offer initiated by the Company, in France or abroad, for the securities of another company listed on one of the regulated markets referred to in Article L.225-148 of the French Commercial Code, or any other type of public offer that complies with the applicable laws and regulations, including notably any public exchange offer, any alternative public purchase or exchange offer, any public purchase or exchange offer combined with a secondary purchase or exchange offer, or any other type of public offer that complies with the applicable laws and regulations.

   However, if a third party launches a public offer for the Company's shares, the Board may not use this authorization during, or in the run-up to, the third-party's offer, unless (i) the Company has already announced its own public offer prior to that period, and (ii) it obtains the prior approval of the shareholders in a General Meeting.

2. Note that, in accordance with Article L.225-132 of the French Commercial Code, in the event of an issue carried out under this authorization of securities carrying immediate or deferred rights to shares of the Company, existing shareholders will waive their pre-emptive rights to subscribe for the shares to be issued on the exercise of the rights attached to said securities.

3. Resolve that if the Board of Directors uses this authorization:

   - The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization – either directly or on the exercise of rights to shares – is set at €8 million. This ceiling is included in the €8 million overall ceiling set in the 18th resolution above and the blanket ceiling set in the 17th resolution for any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period.
of this authorization). However it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company's shares.

- The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €1.8 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This ceiling is included in the €1.8 billion overall ceiling set in the 18th resolution above and the blanket ceiling set in the 17th resolution (or in any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

4. Resolve that the Board of Directors will have full powers to use this authorization, in particular to carry out issues of shares and/or securities carrying immediate or deferred rights to shares of the Company in connection with public offers that fall within the scope of this resolution, and notably to:

- set the exchange ratio as well as any balance to be paid in cash;
- place on record the number of securities tendered to the exchange;
- determine the timing and other terms and conditions of the issue(s) and notably the price and cum-rights date (which may be retroactive) of the securities issued in accordance with this resolution;
- suspend, where appropriate, the exercise of any rights attached to new or existing securities in accordance with the applicable laws and regulations, and make any adjustments in order to take into account the impact of any issues on the Company's capital and set the terms and conditions for protecting the rights of holders of securities carrying rights to the Company's shares, in accordance with the applicable laws, regulations and contractual provisions;
- credit the difference between the issue price of the new shares and their par value to a "contribution premium" account to which all shareholders will have equivalent rights;
- charge all the issuance costs against the contribution premium; and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s), place on record the capital increase(s), amend the Company's bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

5. Authorize the Board of Directors, within the limits set in advance by the Board, to delegate to the Chief Executive Officer or, in agreement with him, to one or more Deputy Chief Executive Officers, the authorization given under this resolution.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 20th resolution of the Annual General Meeting held on April 23, 2015.

TEXT OF THE TWENTIETH RESOLUTION

Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, through a private placement governed by Article L.411-2-II of the French Monetary and Financial Code, which may not be used during, or in the run-up to, a public offer for the Company's shares

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors' special report, in accordance with the applicable laws and regulations and in particular Articles L.225-129 et seq. of the French Commercial Code, notably Articles L.225-129-2, L.225-135 and L.226-136, and also Articles L.228-91 et seq. of said Code and Article L.411-2-II of the French Monetary and Financial Code, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company's capital by issuing, on one or more occasions, ordinary shares and/or securities carrying immediate or deferred rights to new or existing ordinary shares of the Company (either with or without consideration) through a private placement that complies with the conditions set out in Article L.411-2-II of the French Monetary and Financial Code. The Board of Directors will have full discretionary powers to determine the amount and timing of said issue(s), which may be carried out in France or abroad and may be denominated in euros, foreign currency or a monetary unit determined by reference to a basket of currencies.

However, if a third party launches a public offer for the Company's shares, the Board may not use this authorization during, or in the run-up to, the offer, unless it obtains the prior approval of the shareholders in a General Meeting.

2. Resolve that if the Board of Directors uses this authorization:

- The maximum nominal amount of capital increases that may be issued pursuant to this authorization – either directly or on the exercise of rights to shares – will be €8 million. This ceiling is included in the €8 million overall ceiling set in the 18th resolution above and the blanket ceiling set in the 17th resolution (or in any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company's shares.

- The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €1.8 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This ceiling is included in the €1.8 billion overall ceiling set in the 18th resolution above and the blanket ceiling set in the 17th resolution (or in any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

April 24, 2017
3. Resolve to waive shareholders' pre-emptive rights to subscribe for the shares and/or other securities to be issued under this authorization.

4. Resolve that if an issue is not fully subscribed, the Board of Directors may limit the amount of the issue to the subscriptions received, provided that at least three-quarters of the issue is taken up.

5. Note that in the event of an issue of securities carrying rights to shares of the Company, this authorization automatically entails the waiver by shareholders of their pre-emptive rights to subscribe for any shares to be issued on the exercise of the rights attached to said securities.

6. Resolve that the issue price of the shares or securities carrying rights to shares will be at least equal to the minimum price provided for in the laws and regulations in force on the issue date (for information purposes, corresponding at the date of this Meeting, to a price at least equal to the weighted average of the prices quoted for the Company's shares over the three trading days preceding the pricing date, less a discount of no more than 5%).

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to:

- use this authorization and notably to determine the timing, characteristics and other terms and conditions of any issues carried out, including the type and form of securities to be issued, the start and end dates of the subscription period, the issue price and cum-rights date of the issued securities, the method by which the securities will be paid up, and the terms and conditions for exercising the rights attached to securities carrying rights to shares of the Company;
- suspend, where appropriate, the exercise of any rights attached to new or existing securities in accordance with the applicable laws and regulations, and make any adjustments in order to take into account the impact of any issues on the Company's capital and set the terms and conditions for protecting the rights of holders of securities carrying rights to the Company's shares, in accordance with the applicable laws, regulations and contractual provisions;
- in the case of the issuance of debt securities, determine (i) whether the debt will be subordinated or unsubordinated (and the ranking of any subordinated debt), (ii) the interest rate, (iii) the life of the securities (i.e., dated or undated), (iv) their redemption price (which may be fixed or variable and with or without a premium) and repayment terms, depending on market conditions, (v) the terms of their exercise for shares of the Company, and (vi) any other terms and conditions of the issue, including any collateral or other form of guarantee, as well as to amend any of said terms and conditions during the life of the securities concerned;
- charge the issuance costs against the related premiums and deduct from the premiums the amounts necessary to raise the legal reserve to the required level, and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s) and private placement(s), place on record the capital increase(s), amend the Company's bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 21st resolution of the Annual General Meeting held on April 23, 2015.

**PRESENTATION OF THE 21ST RESOLUTION**

In the 21st resolution the Board of Directors is seeking an authorization to increase the number of securities to be issued in the event that an issue carried out with or without pre-emptive subscription rights decided by the Board of Directors pursuant to the 17th, 18th, 19th or 20th resolution is oversubscribed.

The Board of Directors would be able use this authorization at any time except during, or in the run-up to, a public offer for the Company's shares.

The additional securities would be issued at the same price as for the original issue in accordance with the timeframes and ceilings specified in the applicable laws and regulations in force on the issue date (currently, the additional securities must be issued within 30 days of the close of the original subscription period and may not represent more than 15% of the original issue amount). The subceilings and ceilings set in the 17th, 18th, 19th and 20th resolutions would apply if the 21st resolution is used. Any issues of additional securities carried out under this resolution may not result in the ceiling(s) set in the original resolution being exceeded.

This authorization would supersede, as from the date of the Meeting, the authorization granted to the Board of Directors for the same purpose in the 22nd resolution of the Annual General Meeting held on April 23, 2015.

**TEXT OF THE TWENTY-FIRST RESOLUTION**

Authorization for the Board of Directors to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights (pursuant to the 17th, 18th, 19th and 20th resolutions), which may not be used during, or in the run-up to, a public offer for the Company's shares

Having considered the report of the Board of Directors, in accordance with French company law, notably Articles L.225-126-1 and R.225-118 of the French Commercial Code, and subject to the adoption of the 17th, 18th, 19th and 20th resolutions, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights as decided by the Board of Directors pursuant to the 17th, 18th, 19th or 20th resolutions, notably in order to grant an overallocation option in accordance with standard market practices. The additional securities will be issued at the same price as for the original issue in accordance with the conditions and ceilings specified in the applicable laws and regulations (as at the date of this Meeting they must be issued within 30 days of the close of the original subscription period may not represent more than 15% of the original issue amount). In the case of an issue carried out with pre-emptive subscription rights any additional securities issued pursuant to this resolution may only be offered to shareholders in proportion to their existing holdings.

However, if a third party launches a public offer for the Company's shares, the Board may not use this authorization during, or in the run-up to, the offer, unless
it obtains the prior approval of the shareholders in a General Meeting.

2. Resolve that the nominal amount of any capital increases carried out as a result of the shares or other securities issued pursuant to this resolution will be included in the ceiling(s) provided for in the resolution under which the original issue is decided (or in any ceiling(s) set in any resolution with the same purpose that could supersede the resolution concerned during the validity period of this authorization).

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 22nd resolution of the Annual General Meeting held on April 23, 2015.

PRESENTATION OF THE 22ND RESOLUTION

Capitalization of reserves, retained earnings or additional-paid in capital

The purpose of the 22nd resolution is to authorize the Board of Directors to increase the Company's capital by capitalizing reserves, retained earnings or additional paid-in capital brought forward from prior years.

The maximum aggregate nominal amount of any capital increases carried out pursuant to this resolution would be set at €12.5 million, which would be included in the €20 million blanket ceiling set in the 17th resolution.

The Board of Directors would be able to use this authorization at any time except during, or in the run-up to, a public offer for the Company's shares.

This authorization would supersede, as from the date of the Meeting, the authorization granted to the Board of Directors for the same purpose in the 23rd resolution of the Annual General Meeting held on April 23, 2015.

TEXT OF THE TWENTY-SECOND RESOLUTION

Authorization for the Board of Directors to increase the Company's capital by capitalizing reserves, retained earnings or additional paid-in capital, which may not be used during, or in the run-up to, a public offer for the Company's shares

Deliberating in extraordinary session but in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, and having considered the report of the Board of Directors, in accordance with the applicable laws and regulations and in particular with Articles L.225-129-2 and L.225-130 of the French Commercial Code, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company's capital on one or more occasions, to be paid up by capitalizing reserves, retained earnings, additional paid-in capital and/or other items that may be capitalized in accordance with the applicable laws and the Company's bylaws, by issuing bonus shares and/or raising the par value of existing shares. The amounts and timing of such issues will be determined at the Board's discretion.

   However, if a third party launches a public offer for the Company's shares, the Board may not use this authorization during, or in the run-up to, the offer, unless it obtains the prior approval of the shareholders in a General Meeting.

2. Resolve to set the maximum nominal amount of the capital increases that may be carried out pursuant to this authorization at €12.5 million. This ceiling is included in the blanket ceiling set in the 17th resolution (or in any ceiling set in any resolution with the same purpose that could supersede the 17th resolution during the validity period of this authorization). However it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities bearing rights to the Company's shares.

3. Resolve that rights to fractions of shares will not be transferable or tradable and that the corresponding shares will be sold, with the proceeds allocated to the holders of the rights in accordance with the applicable laws.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to use this authorization and to take any and all measures and carry out any and all formalities required to successfully complete the capital increase(s), as well as to place on record the capital increase(s) and amend the Company's bylaws to reflect the new capital.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 23rd resolution of the Annual General Meeting held on April 23, 2015.

Authorizations which may only be used during, or in the run-up to, a public offer for the Company's shares

PRESENTATION OF THE 23RD RESOLUTION

Issue of various shares and/or other securities with pre-emptive subscription rights

The purpose of this resolution is the same as for the 17th resolution but may only be used during, or in the run-up to, a public offer launched by a third party for the
Company's shares.

The maximum aggregate nominal amount of any capital increases carried out pursuant to this resolution — either immediately or on the exercise of rights to shares of the Company — would be set at €8 million (representing approximately 9.6% of the Company's capital). This amount would be included in the blanket ceiling set in the 17th resolution.

The maximum principal amount of any debt securities issued would be set at €2 billion, which would be included in the €2 billion blanket ceiling set in the 17th resolution. The nominal amount of any capital increases resulting from the exercise of rights attached to debt securities carrying rights to shares of the Company would be included in the €6 million ceiling for capital increases set in this resolution (and therefore in the blanket ceiling set for capital increases set in the 17th resolution).

TEXT OF THE TWENTY-THIRD RESOLUTION

Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders, which may only be used during, or in the run-up to, a public offer for the Company's shares.

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors' special report, in accordance with the applicable laws and regulations and in particular Articles L.225-120-2, L.225-132 and L.228-91 et seq. of the French Commercial Code, and having noted that the share capital has been fully paid up, the shareholders:

1. Authorize the Board of Directors — or any representative duly empowered in accordance with the law — to increase the Company's capital by issuing, on one or more occasions, ordinary shares and/or securities carrying immediate or deferred rights to new or existing ordinary shares of the Company (either with or without consideration), with pre-emptive subscription rights for existing shareholders. The Board will have full discretionary powers to determine the amount and timing of said issue(s), which may be carried out in France or abroad and may be denominated in euros, foreign currency or a monetary unit determined by reference to a basket of currencies.

This authorization may only be used during, or in the run-up to, a public offer launched by a third party for the Company's shares.

2. Resolve that if the Board of Directors uses this authorization:

- The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization — either directly or on the exercise of rights to shares — is set at €8 million. This €8 million ceiling (i) represents an overall ceiling on the nominal amount of the capital increases that may be carried out under this authorization and the authorizations granted in the 24th, 25th, 26th, 27th and 28th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization), and (ii) is included in the €20 million blanket ceiling set in the 17th resolution (or in any ceiling set in a resolution with the same purpose that could supersede the 17th resolution during the validity period of this authorization). However it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company's shares.

- The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €2 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This €2 billion ceiling (i) represents an overall ceiling on the principal amount of debt securities that may be issued under this authorization and the authorizations granted in the 24th, 25th, 26th and 27th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization), and (ii) is included in the €2 billion blanket ceiling set in the 17th resolution (or in any ceiling set in a resolution with the same purpose that could supersede the 17th resolution during the validity period of this authorization). However it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code. For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

3. Resolve that existing shareholders will have pre-emptive rights to subscribe for the securities issued pursuant to this authorization, in proportion to their existing holdings.

4. Note that in accordance with the law, the Board of Directors may grant shareholders additional pre-emptive rights to subscribe for any securities not taken up by other shareholders exercising their pre-emptive subscription rights. Such additional rights will also be exercisable in proportion to shareholders' existing holdings and within the limits of their requests.

5. Resolve that if an issue is not taken up in full by shareholders exercising their pre-emptive rights as described above, the Board of Directors may take one or more of the following courses of action, in accordance with the law and in the order of its choice:

- limit the amount of the issue to the subscriptions received, provided that at least three-quarters of the issue is taken up;
- freely allocate all or some of the unsubscribed securities;
- offer some or all of the unsubscribed securities on the open market, either in France or abroad.

6. Resolve that Safran stock warrants may be offered for subscription on the above basis or allocated without consideration to existing shareholders. In the latter case the Board of Directors will have full powers to decide that rights to fractions of warrants will not be transferable or tradable and that the corresponding warrants will be sold.

7. Resolve that the Board of Directors may suspend the exercise of rights to shares of the Company for a maximum period of three months, and make any adjustments in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company's shares.

8. Note that in the event of an issue of securities carrying rights to shares of the Company, this authorization automatically entails the waiver by shareholders of
their pre-emptive rights to subscribe for any shares to be issued on the exercise of the rights attached to said securities.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to:

- use this authorization and notably to determine the timing, characteristics and other terms and conditions of any issues carried out, including the type and form of securities to be issued, the start and end dates of the subscription period, the issue price and cum-rights date of the issued securities, the method by which the securities will be paid up, and the terms and conditions for exercising the rights attached to securities carrying rights to shares of the Company;
- charge the issue costs against the related premiums and deduct from the premiums the amounts necessary to raise the legal reserve to the required level;
- in the case of the issuance of debt securities, determine (i) whether the debt will be subordinated or unsubordinated (and the ranking of any subordinated debt), (ii) the interest rate, (iii) the life of the securities (i.e. dated or undated), (iv) their redemption price (which may be fixed or variable and with or without a premium) and repayment terms, depending on market conditions, (v) the terms of their exercise for shares of the Company, and (vi) any other terms and conditions of the issue, including any collateral or other form of guarantee, as well as to amend any of said terms and conditions during the life of the securities concerned, and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s), place on record the capital increase(s), amend the Company’s bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

This authorization is given for a period of 26 months from the date of this Meeting.

PRESENTATION OF THE 24TH TO 28TH RESOLUTIONS

Issue of shares and/or other securities without pre-emptive subscription rights, and capital increases carried out by capitalizing reserves, retained earnings or additional paid-in capital

These resolutions are similar to the 18th to 22nd resolutions but may only be used during, or in the run-up to, a public offer launched by a third party for the Company’s shares.

The maximum aggregate nominal amount of any capital increases carried out pursuant to the 24th to 26th resolutions – either immediately or on the exercise of rights to shares of the Company – would be set (both per authorization and cumulatively) at €8 million, representing approximately 9.6% of the Company’s capital.

The amounts used under these authorizations would be included in (i) the ceilings set in the 25th and 18th resolutions and (ii) the blanket ceiling set in the 17th resolution. The maximum aggregate nominal amount of all capital increases that may be carried out, either with or without pre-emptive subscription rights, during, or in the run-up to, a public offer for the Company’s shares (pursuant to the 23rd to 28th resolutions) would be set at €8 million (i.e. less than 10% of the Company’s capital).

The maximum principal amount of any debt securities issued under the 24th to 26th resolutions would be set (both per authorization and cumulatively) at €1.8 billion. The amounts used under these authorizations would be included in (i) the €1.8 billion ceiling set in the 18th resolution, (ii) the €2 billion ceiling set in the 25th resolution, and (iii) the €2 billion blanket ceiling set in the 17th resolution. The nominal amount of any capital increases resulting from the exercise of rights attached to debt securities carrying rights to shares of the Company would be included in the €8 million individual and cumulative ceiling set in the 24th to 26th resolutions (and therefore in the ceilings on capital increases set in the 23rd and 17th resolutions).

Any issues carried out under the 27th resolution (increase in the number of securities to be issued in the event of an oversubscribed issue) and any capital increase carried out under the 28th resolution (by capitalizing reserves, retained earnings or additional paid-in capital) would be subject to the same terms and conditions as in the 21st and 22nd resolutions above.

TEXT OF THE TWENTY-FOURTH RESOLUTION

Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, by way of a public offer, which may only be used during, or in the run-up to, a public offer for the Company’s shares

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors’ special report, in accordance with the applicable laws and regulations and in particular Articles L.225-129 et seq. of the French Commercial Code, notably Articles L.225-129-2, L.225-155 and L.225-136 as well as Articles L.226-91 et seq. of said Code and having noted that the share capital has been fully paid up, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company’s capital by issuing, on one or more occasions and through a public offer, ordinary shares of the Company and/or securities carrying immediate or deferred rights to new or existing ordinary shares of the Company (either with or without consideration). The Board will have full discretionary powers to determine the amount and timing of said issue(s), which may be carried out in France or abroad and may be denominated in euros, foreign currency or a monetary unit determined by reference to a basket of currencies.

This authorization may only be used during, or in the run-up to, a public offer launched by a third party for the Company’s shares.

2. Resolve that if the Board of Directors uses this authorization:

- The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization – either directly or on the exercise of rights to shares – is set at €8 million. This €8 million ceiling (i) represents an overall ceiling on the nominal amount of the capital increases that may be carried out

April 24, 2017
under this authorization and the authorizations granted in the 25th, 26th and 27th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization), and (ii) is included in the 68 million ceilings set in the 25th and 18th resolutions and the blanket ceiling set in the 17th resolution (or in any ceiling set in a resolution with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company’s shares.

- The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €1.8 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This €1.8 billion ceiling (i) represents an overall ceiling on the principal amount of debt securities that may be issued under this authorization and the authorizations granted in the 25th, 26th and 27th resolutions of this Annual General Meeting (as well as any authorizations granted in resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization), and (ii) is included in the €2 billion ceiling set in the 23rd resolution, the €1.5 billion ceiling set in the 18th resolution, and the blanket ceiling set in the 17th resolution (or in any ceiling set in a resolution with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

3. Resolve to waive shareholders' pre-emptive rights to subscribe for the shares and/or other securities to be issued under this authorization. However, in accordance with paragraph 5 of Article L.225-135 and Article R.225-131 of the French Commercial Code, the Board of Directors may offer existing shareholders a priority right to subscribe for all or part of any issue(s) carried out under this authorization for a period of no less than three trading days. Such priority rights will not be transferable or tradable and will be exercisable in proportion to shareholders' existing interests.

4. Resolve that if an issue is not taken up in full (including by shareholders exercising their above-mentioned priority rights), the Board of Directors may take one or the other of the following courses of action, in accordance with the law and in the order of its choice:
   - limit the amount of the issue to the subscriptions received, provided that at least three-quarters of the issue is taken up;
   - freely allocate all or some of the unsubscribed securities.

5. Note that in the event of an issue of securities carrying rights to shares of the Company, this authorization automatically entails the waiver by shareholders of their pre-emptive rights to subscribe for any shares to be issued on the exercise of the rights attached to said securities.

6. Resolve that the issue price of the shares or securities carrying rights to shares will be at least equal to the minimum price provided for in the laws and regulations in force on the issue date (for information purposes, corresponding at the date of this Meeting to a price at least equal to the weighted average of the prices quoted for the Company's shares over the three trading days preceding the pricing date, less a discount of no more than 5%).

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to:

- use this authorization and notably to determine the timing, characteristics and other terms and conditions of any issues carried out, including the type and form of securities to be issued, the start and end dates of the subscription period, the issue price and cum-right date of the issued securities, the method by which the securities will be paid up, and the terms and conditions for exercising the rights attached to securities carrying rights to shares of the Company;
- suspend, where appropriate, the exercise of any rights attached to new or existing securities in accordance with the applicable laws and regulations, and make any adjustments in order to take into account the impact of any issues on the Company's capital and set the terms and conditions for protecting the rights of holders of securities carrying rights to the Company's shares, in accordance with the applicable laws, regulations and contractual provisions;
- in the case of the issuance of debt securities, determine (i) whether the debt will be subordinated or unsecured (and the ranking of any subordinated debt), (ii) the interest rate, (iii) the life of the securities (i.e. dated or undated), (iv) their redemption price (which may be fixed or variable and with or without a premium) and repayment terms, depending on market conditions, (v) the terms of their exercise for shares of the Company, and (vi) any other terms and conditions of the issue, including any collateral or other form of guarantee, as well as to amend any of said terms and conditions during the life of the securities concerned;
- charge the issuance costs against the related premiums and deduct from the premiums the amounts necessary to raise the legal reserve to the required level; and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s), place on record the capital increase(s), amend the Company's bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

This authorization is given for a period of 26 months from the date of this Meeting.

TEXT OF THE TWENTY-FIFTH RESOLUTION

Authorization for the Board of Directors to issue shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company, which may only be used during, or in the run-up to, a public offer for the Company's shares

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors' special report, in accordance with the applicable laws and regulations and in particular Articles L.225-129-2 to L.225-129-6, L.225-148 and L.228-91 et seq. of the French Commercial Code, the shareholders:

1. Authorize the Board of Directors to issue shares of the Company and/or securities carrying immediate or deferred rights to the Company's shares as payment for securities of another company tendered to a public exchange offer initiated by the Company. The shareholders further authorize the Board to cancel the pre-emptive rights of existing shareholders to subscribe for the shares and/or other securities issued under this authorization.

April 24, 2017
This authorization may be used in connection with any public exchange offer initiated by the Company, in France or abroad, for the securities of another company listed on one of the regulated markets referred to in Article L.225-148 of the French Commercial Code, or any other type of public offer that complies with the applicable laws and regulations, including notably any public exchange offer, any alternative public purchase or exchange offer, any stock-for-stock and stock-for-cash purchase or exchange offer, any public purchase or exchange offer combined with a secondary purchase or exchange offer, or any other type of public offer that complies with the applicable laws and regulations.

This authorization may only be used during, or in the run-up to, a public offer launched by a third party for the Company's shares.

2. Note that, in accordance with Article L.225-132 of the French Commercial Code, in the event of an issue carried out under this authorization of securities carrying immediate or deferred rights to shares of the Company, existing shareholders will waive their pre-emptive rights to subscribe for the shares to be issued on the exercise of the rights attached to said securities.

3. Resolve that if the Board of Directors uses this authorization:

- The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization – either directly or on the exercise of rights to shares – is set at €8 million. This ceiling is included in the €8 million ceilings set in the 24th resolution, the 23rd resolution and the 18th resolution and the blanket ceiling set in the 17th resolution (or any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company's shares.

- The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €1.8 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This ceiling is included in the €1.8 billion ceiling set in the 24th resolution, the €2 billion ceiling set in the 23rd resolution, the €1.8 billion ceiling set in the 18th resolution and the blanket ceiling set in the 17th resolution (or in any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

4. Resolve that the Board of Directors will have full powers to use this authorization, in particular to carry out issues of shares and/or securities carrying immediate or deferred rights to shares of the Company in connection with public offers that fall within the scope of this resolution, and notably to:

- set the exchange ratio as well as any balance to be paid in cash;
- place on record the number of securities tendered to the exchange;
- determine the timing and other terms and conditions of the issue(s) and notably the price and call rights date (which may be retroactive) of the securities issued in accordance with this resolution;
- suspend, where appropriate, the exercise of any rights attached to new or existing securities in accordance with the applicable laws and regulations, and make any adjustments in order to take into account the impact of any issues on the Company's capital and set the terms and conditions for protecting the rights of holders of securities carrying rights to the Company's shares, in accordance with the applicable laws, regulations and contractual provisions;
- credit the difference between the issue price of the new shares and their par value to a "contribution premium" account to which all shareholders will have equivalent rights;
- charge all the issuance costs against the contribution premium; and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s), place on record the capital increase(s), amend the Company's bylaws to reflect the new capital and carry out all the formalities required for listing the securities issued.

5. Authorize the Board of Directors, within the limits set in advance by the Board, to delegate to the Chief Executive Officer or, in agreement with him and where applicable, to one or more Deputy Chief Executive Officers, the authorization given under this resolution

This authorization is given for a period of 26 months from the date of this Meeting.

TEXT OF THE TWENTY-SIXTH RESOLUTION

Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, through a private placement governed by Article L.411-2-II of the French Monetary and Financial Code, which may only be used during, or in the run-up to, a public offer for the Company's shares

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors' special report, in accordance with the applicable laws and regulations and in particular Articles L.225-129 et seq. of the French Commercial Code, notably Articles L.225-129-2, L.225-135 and L.225-136, as well as Articles L.226-91 et seq. of said Code and Article L.411-2-II of the French Monetary and Financial Code, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company's capital by issuing, on one or more occasions, ordinary shares and/or securities carrying immediate or deferred rights to new or existing ordinary shares of the Company (either with or without consideration) through a private placement that complies with the conditions set out in Article L.411-2-II of the French Monetary and Financial Code. The Board of Directors will have full discretionary powers to determine the amount and timing of said issue(s), which may be carried out in France or abroad and may be denominated in euros, foreign currency or a monetary unit determined by reference to a basket of currencies.

This authorization may only be used during, or in the run-up to, a public offer launched by a third party for the Company's shares.

2. Resolve that if the Board of Directors uses this authorization:

- The maximum nominal amount of the capital increases that may be carried out pursuant to this authorization – either directly or on the exercise of rights to shares – is €8 million. This ceiling is included in the €8 million ceilings set in the 24th, 23rd and 18th resolutions and the blanket ceiling set in the

April 24, 2017
The maximum principal amount of debt securities that may be issued pursuant to this authorization is set at €1.8 billion (or the euro-equivalent of this amount at the issue date for issues in foreign currency or a monetary unit determined by reference to a basket of currencies). This ceiling is included in the €1.8 billion ceiling set in the 24th resolution, the €2 billion ceiling set in the 23rd resolution, the €1.8 billion ceiling set in the 18th resolution and the blanket ceiling set in the 17th resolution (or in any ceilings set in any resolutions with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However it is separate from and does not include the amount of any debt securities whose issue may be decided or authorized by the Board of Directors in accordance with Article L.228-40 of the French Commercial Code.

For the purpose of calculating the above ceilings for debt securities, the euro-equivalent of the principal amount of any debt securities issued in foreign currency will be measured at the issue date.

3. Resolve to waive shareholders’ pre-emptive rights to subscribe for the shares and/or other securities to be issued under this authorization.

4. Resolve that if an issue is not fully subscribed, the Board of Directors may limit the amount of the issue to the subscriptions received, provided that at least three-quarters of the issue is taken up.

5. Note that in the event of an issue of securities carrying rights to shares of the Company, this authorization automatically entails the waiver by shareholders of their pre-emptive rights to subscribe for any shares to be issued on the exercise of the rights attached to said securities.

6. Resolve that the issue price of the shares or securities carrying rights to shares will be at least equal to the minimum price provided for in the laws and regulations in force on the issue date (for information purposes, corresponding at the date of this Meeting, to a price at least equal to the weighted average of the prices quoted for the Company’s shares over the three trading days preceding the pricing date, less a discount of no more than 5%).

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to:

- use this authorization and notably to determine the timing, characteristics and other terms and conditions of any issues carried out, including the type and form of securities to be issued, the start and end dates of the subscription period, the issue price and cum-rights date of the issued securities, the method by which the securities will be paid up, and the terms and conditions for exercising the rights attached to securities carrying rights to shares of the Company;
- suspend, where appropriate, the exercise of any rights attached to new or existing securities in accordance with the applicable laws and regulations, and make any adjustments in order to take into account the impact of any issues on the Company’s capital and set the terms and conditions for protecting the rights of holders of securities carrying rights to the Company’s shares, in accordance with the applicable laws, regulations and contractual provisions;
- in the case of the issuance of debt securities, determine (i) whether the debt should be subordinated or unsubordinated (and the ranking of any subordinated debt), (ii) the interest rate, (iii) the life of the securities (i.e. dated or undated), (iv) their redemption price (which may be fixed or variable and with or without a premium) and repayment terms, depending on market conditions, (v) the terms of their exercise for shares of the Company, and (vi) any other terms and conditions of the issue, including any collateral or other form of guarantee, as well as to amend any of said terms and conditions during the life of the securities concerned;
- charge the issuance costs against the related premiums and deduct from the premiums the amounts necessary to raise the legal reserve to the required level, and more generally
- take all appropriate measures and enter into any and all agreements to successfully complete the issue(s) and private placement(s), place on record the capital increase(s), amend the Company’s bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the securities issued.

This authorization is given for a period of 26 months from the date of this Meeting.

TEXT OF THE TWENTY-SEVENTH RESOLUTION

Authorization for the Board of Directors to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights (pursuant to the 23rd, 24th, 25th or 26th resolutions), which may only be used during, or in the run-up to, a public offer for the Company’s shares

Having considered the report of the Board of Directors, in accordance with French company law, notably Articles L.225-135-1 and R.225-118 of the French Commercial Code, and subject to the adoption of the 23rd, 24th, 25th and 26th resolutions, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights as decided by the Board of Directors pursuant to the 23rd, 24th, 25th or 26th resolutions, notably in order to grant an offer allocation option in accordance with standard market practices. The additional securities will be issued at the same price as for the original issue in accordance with the conditions and ceilings specified in the applicable laws and regulations (as at the date of this Meeting they must be issued within 30 days of the close of the original subscription period and may not represent more than 15% of the original issue amount). In the case of an issue carried out with pre-emptive subscription rights any additional securities issued pursuant to this resolution may only be offered to shareholders in proportion to their existing holdings.

This authorization may only be used during, or in the run-up to, a public offer launched by a third party for the Company’s shares.

2. Resolve that the nominal amount of any capital increases carried out as a result of the shares or other securities issued pursuant to this resolution will be included in the ceiling(s) provided for in the resolution under which the original issue is decided (or in any ceiling(s) set in any resolution with the same purpose that could supersede the resolution concerned during the validity period of this authorization).

This authorization is given for a period of 26 months from the date of this Meeting.
TEXT OF THE TWENTY-EIGHTH RESOLUTION

Authorization for the Board of Directors to increase the Company’s capital by capitalizing reserves, retained earnings or additional paid-in capital, which may only be used during, or in the run-up to, a public offer for the Company’s shares

Deliberating in extraordinary session but in accordance with the rules of quorum and majority applicable to Ordinary General Meetings, and having considered the report of the Board of Directors, in accordance with the applicable laws and regulations and in particular with Articles L.225-129-2 and L.225-130 of the French Commercial Code, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company’s capital on one or more occasions, to be paid up by capitalizing reserves, retained earnings, additional paid-in capital and/or other items that may be capitalized in accordance with the applicable laws and the Company’s bylaws, by issuing bonus shares and/or raising the par value of existing shares. The amounts and timing of such issues will be determined at the Board’s discretion.

This authorization may only be used during, or in the run-up to, a public offer launched by a third party for the Company’s shares.

2. Resolve to set the maximum aggregate nominal amount of the capital increases that may be carried out pursuant to this authorization at €8 million. This ceiling is included in the €8 million ceiling set in the 22th resolution and the blanket ceiling set in the 17th resolution (or in any ceiling set in any resolution with the same purpose that could supersede the aforementioned resolutions during the validity period of this authorization). However, it does not include the nominal amount of any additional shares that may be issued in accordance with the applicable laws and regulations and any contractual provisions to protect the rights of holders of securities carrying rights to the Company’s shares.

3. Resolve that rights to fractions of shares will not be transferable or tradable and that the corresponding shares will be sold, with the proceeds allocated to the holders of the rights in accordance with the applicable laws.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to use this authorization and to take any and all measures and carry out any and all formalities required to successfully complete the capital increase(s), as well as to place on record the capital increased(s) and amend the Company’s bylaws to reflect the new capital.

This authorization is given for a period of 26 months from the date of this Meeting.

Employee share issues

PRESENTATION OF THE 29th RESOLUTION

In the 29th resolution shareholders are invited to authorize the Board of Directors to offer employees who are members of a Safran group employee savings plan the possibility to subscribe for the Company’s shares with a view to involving them more closely in the Group’s development.

This resolution is being submitted in accordance with paragraph 1 of Article L.225-129-6 of the French Commercial Code which states that whenever companies seek authorizations to issue shares to be paid up in cash, they must also submit a resolution on employee share issues.

If this authorization is approved it will necessarily entail the waiver of existing shareholders’ pre-emptive rights to subscribe for the shares covered by the employee share issues concerned.

Employee shareholdings (within the meaning of Article L.225-102 of the French Commercial Code) represented 7.96% of the Company’s capital at March 31, 2017.

Shares issued under this resolution would not be able to represent over 1% of the Company’s capital and would be included in the €20 million blanket ceiling on capital increases set in the 17th resolution.

In accordance with Article L.3332-19 of the French Labor Code, the purchase price of the shares offered to employees may not be lower than the average of the closing prices quoted for the Company’s shares over the 20 trading days preceding the Board of Directors’ decision setting the opening date for the subscription period, less the maximum discount provided for by law as of the date of the Board’s decision.

This authorization would supersede, as from the date of this Meeting, the authorization granted to the Board of Directors for the same purpose in the 24th resolution of the Annual General Meeting held on April 23, 2015.

TEXT OF THE TWENTY-NINTH RESOLUTION

Authorization for the Board of Directors to increase the Company’s capital by issuing ordinary shares to employees who are members of a Safran group employee savings plan, without pre-emptive subscription rights for existing shareholders

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors’ special report, in accordance with Articles L.225-129-2, L.225-129-6 and L.225-138-1 of the French Commercial Code, and Articles L.3332-18 et seq. of the French Labor Code, the shareholders:

1. Authorize the Board of Directors – or any representative duly empowered in accordance with the law – to increase the Company’s capital by issuing, on one or more occasions, ordinary shares of the Company to employees of the Company and of any French or foreign companies affiliated to it within the meaning of Article L.225-180 of the French Commercial Code, who are members of the Group employee savings plan or any company employee savings plan in place

April 24, 2017
within the Safran group. The amounts and timing of such issues will be determined at the Board’s discretion.

2. Resolve that the maximum nominal amount of any capital increases carried out pursuant to this authorization may not represent over 1% of the Company’s capital at the date of the Board of Directors’ decision to carry out the issue. This ceiling is included in the blanket ceiling applicable to capital increases set in the 17th resolution of this Meeting (or in any ceiling set in any resolution with the same purpose that could supersede the 17th resolution during the validity period of this authorization).

3. Resolve that the purchase price of the shares offered to employees under this authorization may not be lower than the average of the closing prices quoted for the Company’s shares over the 20 trading days preceding the Board of Directors’ decision setting the opening date for the subscription period, less the maximum discount provided by law at the date of the Board’s decision.

4. Resolve that the Board of Directors will have full powers to grant to the above beneficiaries, free of consideration and in addition to the shares to be subscribed for in cash, new or existing shares in replacement of all or some of the discount compared with the above reference price and/or the employer's top-up contribution, it being specified that the benefits resulting from such grants may not exceed the legal or regulatory limits as provided for in Articles L.3332-1 to L.3332-21 of the French Labor Code.

5. Note that this authorization automatically entails the waiver by existing shareholders of their pre-emptive rights to subscribe for the shares offered to employees under the issue(s) carried out under this resolution.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to use this authorization, and in particular to (i) set the terms and conditions of the capital increase(s), (ii) draw up the list of companies whose employees will be eligible for the share issue(s), (iii) set the conditions, particularly concerning length of service, that the beneficiaries will have to meet in order to subscribe, on an individual basis or through a corporate mutual fund, for the shares issued pursuant to this authorization, (iv) set the dates and terms and conditions of the issue(s), (v) set the start and end dates of the subscription period(s); (vi) determine the price and the cum-rights date of the shares issued, (vii) determine the method by which the shares will be paid up, (viii) charge the issuance costs against the related premium and deduct from the premium the amounts necessary to raise the legal reserve to the required level, and (ix) more generally, take all appropriate measures and enter into any agreements to successfully complete the share issue(s), place on record the capital increase(s), amend the Company’s bylaws to reflect the new capital and carry out all the formalities required for the admission to trading of the shares issued.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 24th resolution of the Annual General Meeting held on April 23, 2015.

Capital reduction by canceling treasury shares

PRESENTATION OF THE 30TH RESOLUTION

In the 30th resolution, the Board of Directors is seeking an authorization to reduce the Company’s capital by canceling all or some of the treasury shares purchased under share buyback programs previously authorized by shareholders as well as the new program proposed in the 16th resolution.

The Company may choose to cancel treasury shares in order to achieve certain financial objectives, such as actively managing its capital, optimizing its balance sheet structure or offsetting the dilutive impact of capital increases.

In compliance with the applicable law, the number of shares canceled in any 24-month period would not be able to exceed 10% of the Company’s capital.

This authorization would be given for a period of 24 months and would supersede the unused authorization given for the same purpose in the 22nd resolution of the Annual General Meeting held on May 19, 2016.

TEXT OF THE THIRTIETH RESOLUTION

Authorization for the Board of Directors to reduce the Company’s capital by canceling treasury shares

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors’ special report, in accordance with Article L.225-209 of the French Commercial Code, the shareholders:

1. Authorize the Board of Directors to reduce the Company’s capital on one or more occasions, in the proportions and on the dates it deems appropriate, by canceling all or some of the treasury shares held by the Company as a result of implementing a share buyback program. The number of treasury shares that may be canceled within any 24-month period may not exceed 10% of the Company’s capital. This 10% ceiling will apply in the amount of the Company’s capital as adjusted, where applicable, to take into consideration any corporate actions that may be carried out after this Annual General Meeting.

2. Resolve that the Board of Directors will have full powers – which may be delegated in accordance with the law – to implement this resolution and in particular to:
   - set the definitive amount of the capital reduction;
   - set the terms and conditions of the capital reduction and carry it out;
   - charge the difference between the carrying amount of the canceled shares and their par value against any available reserves and additional paid-in capital accounts;
   - place on record the completion of the capital reduction and amend the Company’s bylaws accordingly; and
   - carry out any formalities and other measures and generally do everything necessary to complete the capital reduction.

This authorization is given for a period of 24 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 24th resolution of the Annual General Meeting held on April 23, 2015.
Grant of performance shares free of consideration

PRESENTATION OF THE 31ST RESOLUTION

In the 31st resolution shareholders are invited to authorize the Board of Directors to grant performance shares to (i) employees or certain categories of employees of the Company and/or of other entities in the Safran group, and/or (ii) executive corporate officers of the Company and/or other entities in the Safran group (except the Chairman of the Company’s Board of Directors when the duties of Chairman of the Board and Chief Executive Officer are separated), provided said corporate officers are eligible for such grants under the applicable law.

Performance share grants are a common method used by companies in order to strengthen the motivation and teamwork of beneficiaries and foster their loyalty, while at the same time aligning their interests with those of the company and its shareholders. They are also in line with the strategy of linking the incentives of executive managers to share performance – with the inherent risks and rewards that this involves – in order to encourage long-term reasoning in their actions.

The Board of Directors would determine the beneficiaries of the grants and set the terms and conditions thereof as well as the applicable eligibility criteria.

The shares granted could either be new shares or existing shares bought back by the Company under the terms and conditions provided for by law.

This authorization would entail the waiver by existing shareholders of their pre-emptive rights to subscribe for any shares issued pursuant to this resolution.

This authorization would supersede, as from the date of this Meeting, the authorization granted to the Board of Directors for the same purpose in the 23rd resolution of the Annual General Meeting held on May 19, 2016.

The main characteristics of any performance share grants carried out using this authorization would be as follows:

Performance conditions

The vesting of all of the shares granted would be subject to the achievement of internal and external performance conditions, which would be similar for all beneficiaries and would be assessed over three full consecutive fiscal years, including the year during which the performance shares are granted.

- The two internal performance conditions would count for 70% of the total vested shares and would be based on:
  - ROI (adjusted recurring operating income as defined in section 2.1.2 of the 2016 Registration Document) – 35%
  - FCF (free cash flow as defined in section 2.2.3 of the 2016 Registration Document) – 35%

- The achievement levels for these conditions would be measured by reference to the average of the targets for ROI and FCF set for the fiscal year in which the grant takes place and for the following two fiscal years, as contained in the most recent medium-term plan (MTP) approved by the Board of Directors before the grant date. The following achievement levels would be set for these conditions:
  - lowest achievement level: if 80% of the MTP target is achieved, 40% of the shares contingent on that target will vest;
  - target achievement level: if 100% of the MTP target is achieved, 80% of the shares contingent on that target will vest;
  - highest achievement level (ap): if 125% of the MTP target were achieved, 100% of the shares contingent on that target would vest;
  - between the lowest achievement level and the target level, and between the target level and the highest achievement level, the number of shares that would vest would vary in linear fashion. Below the lowest achievement level, none of the shares contingent on the internal performance condition concerned would vest.

The performance criteria would be measured by comparing results against a same-scope reference base. Consequently, for the first performance share grant carried out after a new entity has been consolidated, the reference base used for measuring the performance criteria will include the data in Safran’s business plan for the acquired entity. Past grants will continue to be measured based on the previous scope of consolidation (i.e. not including the newly-consolidated entity). If an entity is deconsolidated, the reference bases used for past grants will be adjusted to exclude the amounts related to the deconsolidated entity for the years concerned.

- The external performance condition would count for 30% of the total vested shares and would be based on Safran’s total shareholder return (TSR) performance as measured relative to a panel of peer companies operating in the same business sectors as Safran (Aerospace, Defense and Security). The composition of this panel of peer companies may change in order to factor in changes in the structure and operations of the Group or of the peer companies concerned. Currently, these companies comprise Airbus, BAE Systems, Boeing, Finmeccanica, MTU Aero Engines, Rolls-Royce and Thales.

The following achievement levels would be set for this condition:

  - lowest achievement level: if Safran’s TSR were equal to that of the peer companies, 40% of the shares contingent on the external performance condition would vest;
  - target achievement level: if Safran’s TSR were 8 points higher than that of the peer companies, 80% of the shares contingent on the external performance condition would vest;
  - highest achievement level: if Safran’s TSR were 12 points higher than that of the peer companies, 100% of the shares contingent on the external performance condition would vest.

April 24, 2017
performance condition would vest.
- between the lowest achievement level and the target level, and between the target level and the highest achievement level, the number of shares that would vest would vary in linear fashion. Below the lowest achievement level, none of the shares contingent on the external performance condition would vest.

Ceilings
The total number of performance shares granted could not exceed (i) 0.40% of the Company’s capital as at the date on which the Board of Directors decides to make the share grants (main ceiling), and (ii) 0.20% of the Company’s capital in any given fiscal year (sub-ceiling).
In addition, for each grant of performance shares the maximum number of shares granted to each of the Company’s corporate officers would be set at 5% of the total number of shares making up the grant (representing a sub-ceiling of 0.01% of the Company’s capital per corporate officer and fiscal year).

Vesting and lock-up periods
The performance shares granted would be subject to a vesting period set by the Board of Directors, which may not be less than three years.
In addition, any shares granted to the Chief Executive Officer and members of Safran’s Executive Committee would be subject to a lock-up period of at least one year following their vesting date.
In accordance with the Company’s compensation policy, if any performance shares were granted to the Chief Executive Officer, he would be required to hold in registered form a proportion of his vested shares, as set by the Board of Directors, until his duties as Chief Executive Officer cease.
Each beneficiary would also be required to give a formal undertaking to refrain from hedging the risk related to their performance shares until they may freely transfer the shares granted (i.e. the end of the vesting period or, where applicable, the end of the lock-up period set by the Board of Directors, depending on the beneficiaries concerned).
The shares granted could either be new shares or existing shares bought back by the Company under the terms and conditions provided for by law.
This authorization would entail the waiver by existing shareholders of their pre-emptive rights to subscribe for any shares issued pursuant to this resolution.

Term
This authorization would be granted for a period of 26 months from the date of this Meeting.

Anticipated use
If this authorization is approved by shareholders, in line with its long-term compensation policy, the Board of Directors intends to set up annual performance share plans which will have the characteristics and be subject to the performance conditions and ceilings described above.

TEXT OF THE THIRTY-FIRST RESOLUTION

Authorization for the Board of Directors to grant existing or new shares of the Company, free of consideration, to employees and corporate officers of the Company and other Safran group entities, with a waiver of shareholders’ pre-emptive subscription rights

Deliberating in accordance with the rules of quorum and majority applicable to Extraordinary General Meetings and having considered the report of the Board of Directors and the Statutory Auditors’ special report, in accordance with Articles L.225-197-1 et seq. of the French Commercial Code, the shareholders:

1. Authorize the Board of Directors to grant, on one or more occasions, existing or new Safran shares, free of consideration, to (i) employees or certain categories of employees of the Company and/or of companies or groups affiliated to it within the meaning of Article L.225-197-2 of the French Commercial Code, and/or (ii) corporate officers of the Company and/or of related companies or groups within the meaning of Article L.225-197-2 of the French Commercial Code (except for the Chairman of the Company’s Board of Directors when the duties of Chairman of the Board and Chief Executive Officer are separated), provided said corporate officers are eligible for such grants under the applicable law. The amounts and timing of such grants will be determined at the Board’s discretion.

2. Resolve that the total number of existing or new shares granted free of consideration pursuant to this authorization may not exceed (i) 0.40% of the Company’s capital at the date of the Board of Directors’ decision to grant free shares, or (ii) 0.20% of the Company’s capital in any given fiscal year.

3. Resolve that the shares granted pursuant to this authorization will be subject to performance conditions set by the Board of Directors based on the recommendations of the Appointments and Compensation Committee and assessed over a minimum period of three consecutive fiscal years, including the year of grant.

4. Resolve that for each grant of free shares, any shares granted to the Company’s corporate officers in accordance with the conditions provided for by law may not represent over 5% of the total number of shares making up the grant (per corporate officer).

5. Resolve that the shares granted will be subject to a vesting period which will be set by the Board of Directors but may not be less than three years, followed, in certain cases, by a lock-up period whose duration will also be set by the Board of Directors.

6. Resolve that any free shares granted to the Company’s corporate officers and members of the Executive Committee will be subject to a lock-up period which will be set by the Board of Directors but may not be less than one year as from the vesting date.

7. Resolve that the shares will vest before the expiration of the above-mentioned vesting period and will be freely transferable before the expiration of the above-mentioned lock-up period in the event that the beneficiary becomes disabled, within the meaning of the definition set down in the second or third categories under Article L.341-4 of the French Social Security Code (or the equivalent in any foreign country).

8. Note that if new shares are issued for the purpose of allocating the free shares, this authorization will result in capital increases paid up by capitalizing reserves, retained earnings or additional paid-in capital as the shares vest, as well as a corresponding waiver by shareholders of their pre-emptive rights to

April 24, 2017
subscribe for the shares issued as part of these capital increases.

The shareholders give full powers to the Board of Directors – or any representative duly empowered in accordance with the law – to use this authorization within the limits set by the applicable laws and regulations and in particular to:

- determine if the shares granted free of consideration will be new shares or existing shares, it being specified that the Board may change its choice before the vesting date;
- draw up the list or categories of eligible beneficiaries;
- set the applicable performance and vesting conditions, notably the duration of the vesting period and lock-up period, particularly concerning the Company's corporate officers and members of the Executive Committee;
- provide for the possibility to provisionally suspend the beneficiaries' rights to receive the shares;
- place on record the vesting dates of the shares granted and the dates from which the shares may be freely transferred or sold;

- make any adjustments required during the vesting period to the number of free shares granted in order to protect the rights of beneficiaries, it being specified that the shares granted in connection with any such adjustments will be deemed to have been granted on the same date as the initial grant;
- in the event of the issue of new shares, (i) deduct, where applicable, from reserves, retained earnings or additional paid-in capital, the amounts necessary to pay up the shares, (ii) place on record the capital increases carried out pursuant to this authorization, (iii) amend the Company's bylaws to reflect the new capital, and generally
- take all appropriate measures and enter into any and all agreements to successfully complete the share grants.

This authorization is given for a period of 26 months from the date of this Meeting and supersedes the authorization given to the Board of Directors for the same purpose in the 23rd resolution of the Annual General Meeting held on May 19, 2016.

RESOLUTION CONCERNING POWERS TO CARRY OUT FORMALITIES

PRESENTATION OF THE 32ND RESOLUTION

The 32nd resolution concerns the powers that are necessary to carry out the filing and other legal formalities required for the resolutions adopted at the Meeting.

TEXT OF THE THIRTY-SECOND RESOLUTION

Powers to carry out formalities

The shareholders give full powers to the bearer of an original, extract or copy of the minutes of this Meeting to carry out any and all filing, publication, declaration and other formalities required by the applicable laws and regulations.
PROFILES OF THE NOMINEES TO THE BOARD OF DIRECTORS

Re-appointment of a Director proposed by the Board of Directors

Shareholders are invited to re-appoint Odile Desforges as a Director (see profile below).

Odile Desforges
Independent Director
Member and Chair of the Audit and Risk Committee
3, rue Henri Heine – 75016 Paris, France
Number of Safran shares held: 500

Profile – Expertise and experience
Born in 1950, Odile Desforges is a graduate of the École Centrale Paris engineering school.

She began her career as a Research Analyst at the French Transport Research Institute (Institut de Recherche des Transports). In 1981, she joined the Renault group as planning officer for the Automobile Planning Department before becoming a product engineer on the R19 and then for the M1 range (1984-1986). In 1986, she moved to the Purchasing Department as Head of the Exterior Equipment Unit. She was later appointed Director of Body Hardware Purchasing for the joint Renault Volvo Car Purchasing Organization in 1992, and for Renault alone in 1994. In March 1999, she became Executive Vice President of the Renault V-Mark group, in charge of 3P (Product Planning, Product Development, Purchasing Project). In 2001, she was appointed President of AB Volvo’s 3P Business Unit.

In 2003, Odile Desforges became Senior Vice President, Renault Purchasing, Chair and CEO of the Renault Nissan Purchasing Organization (RNPO) and a member of the Renault Management Committee.

From 2009 to July 2012, she was Director of Engineering and Quality, and a member of Renault’s Executive Committee.

She retired on August 1, 2012.

Odile Desforges brings to the Board her experience as a Director and former senior executive of international industrial groups, as well as performance and management control expertise and acknowledged experience in purchasing, R&D projects and innovation.

Offices and positions held in French and non-French companies

Current offices and positions

SAFRAN GROUP

- Director of Safran

NON-GROUP

- Director and a member of the Audit Committee of:
  - Dassault Systèmes (listed company)
  - Faurecia (listed company) since June 2016

- Director and a member of the Audit Committee, the Nomination Committee and the Management Development and Remuneration Committee of Johnson Matthey plc (listed company) (UK)

- Director and a member of the Strategy Committee of lmerys (listed company) since May 2016

Offices and positions that expired in the last five years

SAFRAN GROUP

- Director and a member of the Nomination and Compensation Committee of Sequana (listed company) until May 2016

- Director of:
  - GIE REGIE NOV until January 2013
  - Renault España SA (Spain) until December 2012
  - RNTBCI until June 2012
  - Renault Nissan BV (Netherlands) until June 2012

April 24, 2017
Appointment of a new Director proposed by the Board of Directors

Shareholders are invited to appoint Hélène Auriol Potier as a Director (see profile below).

Hélène Auriol Potier
Microsoft EMEA – 39 Quai du Président Roosevelt, 92130 Issy-les-Moulineaux, France

Profile – Expertise and experience

Born on November 26, 1962, Hélène Auriol Potier, a French national, graduated as an engineer from the Ecole Nationale Supérieure des Télécommunications de Paris and completed an Executive Program MBA at INSEAD.

Hélène Auriol-Potier built her career in the digital technologies and telecommunications industry in the United States, Europe, Africa and Asia.

She started her career in New York at France Telecom in 1986.

In 1990, she joined the Canadian mobile technology company Nortel, where she spent 16 years and successively held several management positions including Vice President Mobile Pre-Sale division and Vice President EMEA, Services & Operations.

In 2006, she joined Dell as Managing Director, in charge of the Africa and Mediterranean region and as member of the Executive Committee of Dell Emerging Markets.

She joined Microsoft in 2009 as General Manager – Enterprises, Public Sector and Partners – and as a member of the Executive Committee of Microsoft France. She was then appointed General Manager of Microsoft Singapore and member of the Executive Committee of Microsoft Asia-Pacific. In 2013, she was appointed General Manager of Microsoft Dynamics, Western Europe.

Hélène Auriol Potier has been General Manager of Microsoft Western Europe Public Sector since 2016.

Offices and positions held in French and non-French companies

Current offices and positions

SAFRAN GROUP
None

NON-GROUP
♦ Director, Chair of the Ethics Committee and member of the Compensation Committee of Ipsan (listed company)
♦ Member of the Supervisory Board of Oddo & Cie

Offices and positions that expired in the last five years

SAFRAN GROUP
None

NON-GROUP
♦ Director of Faiveley Transport (listed company)
Appointment of a new Director proposed by the Board of Directors

Shareholders are invited to appoint Patrick Pélista as a Director (see profile below).

Patrick Pélista
Meta Consulting LLC – 912 Geneva Avenue, San Francisco, CA 94122, United States

Profile – Expertise and experience

Born in 1955, Patrick Pélista is a graduate of the École Polytechnique and of the Ecole Nationale des Ponts et Chaussées engineering school, and holds a PhD in socioeconomics from the Ecole des Hautes Études en Sciences Sociales.

He joined Renault in 1984 as a shop foreman at the Flins plant and from 1985 he contributed to the creation of the Renault Twingo and served in several engineering positions at Vehicle Engineering, where he became Senior Vice President in 1998 and joined the Renault Management Committee. Following the signature of the Alliance between Renault and Nissan in 1999, he joined Nissan in Tokyo as Executive Vice President in charge of Corporate and Product Planning, Design and Programs, sitting on the Executive Committee of Nissan and the Executive Board of the Alliance. In 2005, he returned to Renault as Executive Vice President in charge of Corporate and Product Planning, Design and Programs, and joined the Executive Committee. Patrick Pélista served as Chief Operating Officer of the Renault group from October 2008 to April 2011, before his departure in August 2012.

From September 2012 to July 2015, he was Chief Automotive Officer and Executive Vice President of Salesforce.com with responsibility for strategy execution and promoting social media, mobility and cloud computing technologies to the automotive industry.

In August 2015, he created Meta Consulting LLC, of which he is President.

Offices and positions held in French and non-French companies

Current offices and positions
SAFRAN GROUP
None
NON-GROUP
♦ President of Morpho Detection, LLC (United States)
Offices and positions that expired in the last five years
SAFRAN GROUP
None
NON-GROUP
♦ Chairman of the Ecole Nationale des Ponts et Chaussées until July 2013

April 24, 2017

44
Appointment of a new Director proposed by the Board of Directors

Shareholders are invited to appoint Sophie Zurquiyah as a Director (see profile below).

Sophie Zurquiyah
CGG – 33, avenue du Maine, 75015 Paris, France

Profile – Expertise and experience

Born in 1967, Sophie Zurquiyah has dual French and American nationality. She is a graduate of the Ecole Centrale de Paris and holds a Master of Science in numerical analysis from the Pierre and Marie Curie University (Paris VI), as well as a Master of Science in aerospace engineering from the University of Colorado.

Having started her career with Schlumberger in 1991 as a geophysics engineer, she held a variety of positions in Engineering and Manufacturing in France and the United States, before being appointed as General Manager for the Schlumberger South Latin America Region, based in Rio de Janeiro in 2003. Between 2005 and 2007, she served as Human Resources Director for Oilfield Services at Schlumberger, and then as Chief Information Officer for the Schlumberger group at its headquarters in Paris until 2009. In 2009, she was appointed President of Schlumberger Data & Consulting Services in Houston, where she remained until 2012.

Sophie Zurquiyah joined CGG on February 4, 2013 as Senior Executive Vice-President of the Geology, Geophysics & Reservoir (GGR) business. On September 1, 2015, she was appointed Chief Operating Officer in charge of Technology and Global Operational Excellence, in addition to her operating responsibilities for product lines in the GGR segment. She is currently a member of the Executive Committee of the CGG group.

Offices and positions held in French and non-French companies

Current offices and positions

SAFRAN GROUP
None

NON-GROUP
+ Corporate officer of CGG Services, Inc. (United States) since 2013
+ Director of PetroEdge (United Kingdom) since 2016

Offices and positions that expired in the last five years

SAFRAN GROUP
None

NON-GROUP
+ Corporate officer of Schlumberger Technology Corporation (United States) from 2000 to 2013
+ Director of Magnitude Microseismic. LLC (United States) from 2013 to 2015
The resolutions approved by the Board of Directors on April 19, 2017, which will be submitted for approval at the Annual General Meeting on June 15, 2017, provide for the authorizations summarized below to be granted to the Board of Directors.

<table>
<thead>
<tr>
<th>Type of authorization</th>
<th>Date of authorization</th>
<th>Term</th>
<th>Ceiling (maximum nominal amount of capital increase and maximum principal amount of debt securities)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorization for the Board of Directors to carry out a share buyback program</td>
<td>June 15, 2017 AGM (15th resolution)</td>
<td>18 months</td>
<td>€5.9 billion (10% of the Company's capital)</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders, which may not be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (17th resolution)</td>
<td>20 months</td>
<td>€20 million (€2 billion (debt securities))</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, by way of a public offer, which may not be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (16th resolution)</td>
<td>20 months</td>
<td>€8 million^{(1)}</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to issue shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company, which may not be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (19th resolution)</td>
<td>26 months</td>
<td>€8 million^{(1)} (€1.6 billion (debt securities))^{(2)}</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, through a private placement governed by Article L.411-8-II of the French Monetary and Financial Code, which may not be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (20th resolution)</td>
<td>26 months</td>
<td>€8 million^{(1)} (€1.6 billion (debt securities))^{(2)}</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights for existing shareholders (pursuant to the 17th, 18th, 19th and 20th resolutions), which may not be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (21st resolution)</td>
<td>26 months</td>
<td>15% of the original issue^{(2)}</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company's capital by capitalizing reserves, retained earnings or additional paid-in capital, which may not be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (22nd resolution)</td>
<td>26 months</td>
<td>€12.5 million^{(1)}</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders, which may only be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (23rd resolution)</td>
<td>26 months</td>
<td>€8 million^{(1)} (€2 billion (debt securities))^{(2)}</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company's capital by issuing ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, by way of a public offer, which may only be used during, or in the run-up to, a public offer for the Company's shares</td>
<td>June 15, 2017 AGM (24th resolution)</td>
<td>26 months</td>
<td>€8 million^{(1)} (€1.6 billion (debt securities))^{(2)}</td>
</tr>
</tbody>
</table>

April 24, 2017
<table>
<thead>
<tr>
<th>Authorization</th>
<th>Date of Resolution</th>
<th>Duration</th>
<th>Amount</th>
</tr>
</thead>
</table>
| Authorization for the Board of Directors to issue shares and/or securities   | June 15, 2017 AGM  | 26 months| €8 million
| carrying rights to shares of the Company, without pre-emptive subscription  | (25th resolution)  |          | (debt securities)
| rights for existing shareholders, in the event of a public exchange offer    |                     |          |        |
| initiated by the Company, which may only be used during, or in the run-up to|                     |          |        |
| a public offer for the Company's shares                                      |                     |          |        |
| Authorization for the Board of Directors to increase the Company's capital   | June 15, 2017 AGM  | 26 months| €8 million
| by issuing ordinary shares and/or securities carrying rights to                | (26th resolution)  |          | (debt securities)
| shares of the Company, without pre-emptive subscription rights for           |                     |          |        |
| existing shareholders, through a private placement governed by Article L.411-2-21|                     |          |        |
| of the French Monetary and Financial Code, which may only be used during, or  |                     |          |        |
| in the run-up to, a public offer for the Company's shares                     |                     |          |        |
| Authorization for the Board of Directors to increase the number of securities | June 15, 2017 AGM  | 26 months| 15% of the original issue |
| included in an issue carried out with or without pre-emptive subscription    | (27th resolution)  |          |        |
| rights for existing shareholders (pursuant to the 23rd, 24th, 25th or 26th  |                     |          |        |
| resolutions), which may only be used during, or in the run-up to, a public   |                     |          |        |
| offer for the Company's shares                                               |                     |          |        |
| Authorization for the Board of Directors to increase the Company's capital   | June 15, 2017 AGM  | 26 months| €8 million
| by capitalizing reserves, retained earnings or additional paid-in capital,    | (28th resolution)  |          |        |
| which may only be used during, or in the run-up to, a public offer for the   |                     |          |        |
| Company's shares                                                             |                     |          |        |
| Authorization for the Board of Directors to increase the Company's capital   | June 15, 2017 AGM  | 26 months| 1% of the Company's capital |
| by issuing ordinary shares to employees who are members of a Safran group    | (29th resolution)  |          |        |
| employee savings plan, without pre-emptive subscription rights for           |                     |          |        |
| existing shareholders                                                         |                     |          |        |
| Authorization for the Board of Directors to reduce the Company's capital     | June 15, 2017 AGM  | 24 months| 10% of the Company's capital |
| by canceling treasury shares                                                 | (30th resolution)  |          |        |
| Authorization for the Board of Directors to grant existing or new shares of  | June 15, 2017 AGM  | 26 months| 0.40% of the Company's capital |
| the Company, free of consideration, to employees and corporate               | (31st resolution)  |          | at the grant date |
| officers of the Company and other Safran group entities, with a waiver of   |                     |          |        |
| shareholders' pre-emptive subscription rights                               |                     |          |        |

(a) This amount is included in the €20 million ceiling for capital increases set in the 17th resolution.
(b) This amount is included in the €13 billion ceiling for capital increases set in the 17th resolution.
(c) This amount is included in the €9 million ceiling for capital increases set in the 18th resolution.
(d) This amount is included in the €1.8 billion ceiling for issues of debt securities set in the 18th resolution.
(e) The ceilings applicable to the 17th, 18th, 19th and 20th resolutions of the June 15, 2017 AGM still apply if the option provided for in the 21st resolution is used.
(f) This amount is included in the €8 million ceiling for capital increases set in the 22nd resolution.
(g) This amount is included in the €2 billion ceiling for issues of debt securities set in the 22nd resolution.
(h) This amount is included in the €8 million ceiling for capital increases set in the 24th resolution.
(i) This amount is included in the €1.8 billion ceiling for issues of debt securities set in the 24th resolution.
(j) The ceilings applicable to the 23rd, 24th, 25th and 26th resolutions of the June 15, 2017 AGM will still apply if the option provided for in the 27th resolution is used.

April 24, 2017
# SUMMARY TABLE OF AUTHORIZATIONS IN FORCE ALREADY GRANTED TO THE BOARD OF DIRECTORS

The financial authorizations in force, already granted by shareholders to the Board of Directors, are summarized below.

<table>
<thead>
<tr>
<th>Type of authorization</th>
<th>Date of the authorization, term and expiration</th>
<th>Ceiling (maximum nominal amount of capital increases and maximum principal amount of debt securities)</th>
<th>Amount used at Dec 31, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorization for the Board of Directors to issue ordinary shares and/or securities carrying rights to shares of the Company, with pre-emptive subscription rights for existing shareholders</td>
<td>April 23, 2016 AGM (18th resolution) 26 months, i.e., until June 22, 2017</td>
<td>€20 million&lt;br&gt;€2 billion (debt securities)</td>
<td>None</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to issue ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, by way of a public offer</td>
<td>April 23, 2016 AGM (19th resolution) 26 months, i.e., until June 22, 2017</td>
<td>€6 billion&lt;br&gt;€1.3 billion (debt securities)</td>
<td>None</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to issue shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, in the event of a public exchange offer initiated by the Company</td>
<td>April 23, 2016 AGM (20th resolution) 26 months, i.e., until June 22, 2017</td>
<td>€8 million&lt;br&gt;€1.3 billion (debt securities)</td>
<td>None</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to issue ordinary shares and/or securities carrying rights to shares of the Company, without pre-emptive subscription rights for existing shareholders, through a private placement governed by Article L 411-2-II of the French Monetary and Financial Code</td>
<td>April 23, 2015 AGM (21st resolution) 26 months, i.e., until June 22, 2017</td>
<td>€8 million&lt;br&gt;€1.3 billion (debt securities)</td>
<td>Amount used: €650 million (See section 7.2.3.2 of the 2016 Registration Document) Amount remaining: €50 million</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the number of securities included in an issue carried out with or without pre-emptive subscription rights</td>
<td>April 23, 2016 AGM (22nd resolution) 26 months, i.e., until June 22, 2017</td>
<td>15% of the original issue</td>
<td>None</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to increase the Company’s capital by capitalizing reserves, retained earnings or additional paid-in capital</td>
<td>April 23, 2015 AGM (23rd resolution) 26 months, i.e., until June 22, 2017</td>
<td>€12.5 million</td>
<td>None</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to issue ordinary shares to employees who are members of a Safran group employee savings plan, without pre-emptive subscription rights for existing shareholders</td>
<td>April 23, 2015 AGM (24th resolution) 26 months, i.e., until June 22, 2017</td>
<td>1% of the Company’s capital</td>
<td>None</td>
</tr>
<tr>
<td>Blanket ceilings on authorizations to issue shares and/or other securities</td>
<td>April 23, 2016 AGM (25th resolution)</td>
<td>Sub-ceiling: €25 million for the 16th, 19th, 20th and 21st resolutions of the April 23, 2015 AGM. Sub-ceiling: €2 billion (debt securities) for the 18th, 19th, 20th and 21st resolutions of the April 23, 2015 AGM. Blanket ceiling of €30 million for the 18th, 19th, 20th, 21st, 22nd and 24th resolutions of the April 23, 2015 AGM</td>
<td>None</td>
</tr>
<tr>
<td>Type of authorization</td>
<td>Date of the authorization, term and expiration</td>
<td>Ceiling (maximum nominal amount of capital increases and maximum principal amount of debt securities)</td>
<td>Amount used at Dec. 31, 2016</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Authorization for the Board of Directors to grant existing or new shares of the Company, free of consideration, to employees and corporate officers of the Company and other Satran group entities, with a waiver of shareholders' pre-emptive subscription rights</td>
<td>May 19, 2016 AGM (23rd resolution), 14 months, i.e., until July 16, 2017</td>
<td>0.35% of the Company’s capital at the grant date</td>
<td>Amount used at Dec. 31, 2016: 0.13% of the capitalAmount remaining at Dec. 31, 2016: 0.21% of the capitalAmount used at March 30, 2017: 0.07% of the capitalAmount remaining at March 30, 2017: 0.09% of the capital (see section 7.3.7.1 of the 2016 Registration Document)</td>
</tr>
</tbody>
</table>

(1) This amount is included in the €25 million sub-ceiling for capital increases set at the April 23, 2015 AGM (22nd resolution).

(2) This amount is included in the €2 billion sub-ceiling for issues of debt securities set at the April 23, 2015 AGM (25th resolution).

(3) This amount is included in the €30 million blanket ceiling for capital increases set at the April 23, 2015 AGM (25th resolution).

(4) This amount is included in the €8 million sub-ceiling for capital increases without pre-emptive subscription rights set at the April 23, 2015 AGM (19th resolution).

(5) This amount is included in the €1.3 billion sub-ceiling for issues of debt securities without pre-emptive subscription rights set at the April 23, 2015 AGM (19th resolution).

(6) The ceilings applicable to the 18th, 19th, 20th and 21st resolutions of the April 23, 2015 AGM still apply if the option provided for in the 22nd resolution is used.